Document:

EX-10.13

 Exhibit 10.13 
 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. 
 Confidential Treatment Requested Under 
 17 C.F.R. Sections 200.80(b)(4)
and 230.406 
 SUPPLY, SERVICE, AND SUPPORT AGREEMENT 
 This Supply, Service, and Support Agreement (the “Agreement”) is effective as of the date of last signature found below (the “Effective Date”) between Illumina, Inc., a
Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA 92122 (“Illumina”) and Foundation Medicine Inc. , having a place of business at One Kendall Square, Suite B3501, Cambridge, MA, 02139
(“Customer”). Customer and Illumina may be referred to herein as “Party” or “Parties.” 

The Parties agree as follows: 
 1.
Definitions. The following terms have these meanings. 
 “Affiliate(s)” means with respect to a Party, any
entity that, directly or indirectly, controls, is controlled by or is under common control with such Party for so long as such control exists. For purposes of this definition, an entity has control of another entity if it has the direct or indirect
ability or power to direct or cause the direction of management policies of such other entity or otherwise direct the affairs of such other entity, whether through ownership of the voting securities of such other entity, by contract or otherwise.

 “Affiliate Application Specific IP” means the Intellectual Property Rights of an Affiliate of Illumina that
pertain to the Product (and use thereof) only with regard to specific field(s) or specific application(s). Affiliate Application Specific IP excludes all Core IP. By way of non-limiting example, Intellectual Property Rights for NIPT, for specific
diagnostic methods, for specific forensic methods, or for specific nucleic acid biomarkers, sequences, or combinations of biomarkers or sequences are examples of Affiliate Application Specific IP. Affiliate Application Specific IP is a subset of
Application Specific IP. 
 “Application Specific IP” means the Illumina Intellectual Property Rights, inclusive
of Affiliate Application Specific IP, that pertain to the Product (and use thereof) only with regard to specific field(s) or specific application(s). Application Specific IP excludes all Core IP. By way of non-limiting example, Illumina Intellectual
Property Rights for NIPT, for specific diagnostic methods, for specific forensic methods, or for specific nucleic acid biomarkers, sequences, or combinations of biomarkers or sequences are examples of Application Specific IP. 

“Base Price” means, with respect to (x) any [...***...], (i) for [...***...] of the Term,
Illumina’s [...***...] for such [...***...] in effect as of the Effective Date, and (ii) for [...***...] of the Term thereafter, the lesser of (A) [...***...], and (B) [...***...], and (y) any
[...***...], Illumina’s [...***...]. For the avoidance of doubt, Illumina’s [...***...]. 

“Consumable(s)” means Illumina-Branded reagents and consumable items that are intended by Illumina for use with, and are
to be consumed through the use of Illumina Hardware. Consumables are either TG Consumables or Non-TG Consumables (including Temporary Consumables). TG Consumables are designated with the pre-fix “TG” in their part number, which prefix
indicates that they have the attributes detailed in Sections 10-12. “Non-TG Consumables” are all Consumables other than TG Consumables. All references in this Agreement to Consumables means both TG Consumables and Non-TG Consumables
unless specified otherwise in this Agreement. 
 “Core IP” means Illumina Intellectual Property Rights that
pertain to or cover aspects or features of the Product (or use thereof) that are common to the Products in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP specifically excludes any and all Intellectual
Property Rights relating to NIPT. 
 “Customer Use” means use in the Field, specifically excluding any use that
(i) is not in accordance with the Product’s Specifications or Documentation, (ii) requires grants of rights or a license to Application Specific IP or Affiliate Application Specific IP, (iii) is a re-use of a previously used
Consumable, (iv) is the disassembling, reverse-engineering, reverse-compiling, or reverse-assembling of the Product, (v) is the separation, extraction, or isolation of components of Consumables or other unauthorized analysis of the
Consumables, (vi) gains access to or determines the methods of operation of the Product, (vii) is the use of a non-Illumina reagent/consumable with Illumina Hardware (unless the Specifications or Documentation state otherwise), or
(viii) is the transfer to a third-party of, or sub-licensing of, Software or third-party software. 

“Country” or “Countries” means the United States of America including its territories and possessions.

  
 ***Confidential
Treatment Requested*** 

  

 “Documentation” means Illumina’s user manual, package insert, and
similar documentation, for the Product in effect on the date that the Product ships. Documentation may be provided (including by reference to a website) with the Product at the time of shipment or provided electronically from Illumina. 

“Existing Instruments” means Illumina Hardware that was purchased by Customer from Illumina or provided by Illumina prior
to the Effective Date and that Customer intends to use with the Consumables purchased under this Agreement. 

“Facility” or “Facilities” means laboratories in the Country(ies) that are either owned by or leased by
Customer. 
 “Field” means Oncology [...***...]. 

“Illumina Branded” means products that bear Illumina branding or the branding of any Affiliate of Illumina. 

“Illumina Hardware” means Illumina-Branded instruments, accessories, and peripherals sold by Illumina or its Affiliates.

 “Illumina Intellectual Property Rights” means all Intellectual Property Rights owned or controlled by
Illumina or Affiliates of Illumina as of the date of shipment of the Product from Illumina. Application Specific IP, inclusive of Affiliate Application Specific IP, and Core IP are separate, non-overlapping, subsets within the Illumina Intellectual
Property Rights. 
 “Intellectual Property Right(s)” means all rights in patent, copyrights, trade secrets,
know-how, trademark, service mark and trade dress rights and other industrial or intellectual property rights under the laws of any jurisdiction, together with all applications therefor and registrations thereto. 

“Net Price” means [...***...]. 
 “NIPT” means non-invasive pre-natal testing. 
 “Third
Party IP” means the Intellectual Property Rights of third parties wherein third parties for purposes of this definition specifically exclude Affiliates of Illumina. 
 “Product(s)” means the Consumables, Illumina Hardware, and Software that are offered for sale under, purchased under or otherwise governed by the terms and conditions of this Agreement.

 “[...***...] Agreement” means the document to be entered into by and between Illumina and Customer that
will define the responsibilities of each Party with respect [...***...]. 
 “Research” means
(i) internal research, and (ii) research services provided to third-parties.. Research Use includes [...***...]. 

“Research Use” means use for Research, specifically excluding any use that (i) is not in accordance with the
Product’s Specifications or Documentation, (ii) requires grant of rights or a license to Application Specific IP or Affiliate Application Specific IP, (iii) is a re-use of a previously used Consumable, (iv) is the disassembling,
reverse-engineering, reverse-compiling, or reverse-assembling of the Product, (v) is the separation, extraction, or isolation of components of Consumables or other unauthorized analysis of the Consumables, (vi) gains access to or
determines the methods of operation of the Product, (vii) is the use of a non-Illumina reagent/consumable with Illumina Hardware (unless the Specifications or Documentation state otherwise), or (viii) is the transfer to a third-party of,
or sub-licensing of, Software or third-party software. 
 “Sample [...***...]” means [...***...].
For clarity, Sample [...***...] includes at least the following steps: [...***...]. 
 “Service
Contracts” means the Product maintenance, support, and technical services products that Customer may purchase as set forth in Appendix I. Service Contracts are subject to their separate conditions, limitations, and terms and conditions that
are hereby incorporated herein by reference. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 2 

 “Software” means Illumina-Branded software (e.g., Hardware operating
software, data analysis software), regardless of whether it is embedded in or installed on Illumina Hardware or provided separately. 
 “Specifications” means Illumina’s written specifications for a Product in effect for that Product on the date that the Product ships. 

“Temporary Consumable(s)” means Non-TG Consumables purchased under this Agreement that Customer intends to use for
Customer Use and for which a TG version of such Consumable is not available from Illumina. Temporary Consumables are set forth in Exhibit A, as may be amended from time to time by the Parties; provided, however, that Non-TG Consumables purchased by
Customer (i) after the Effective Date for Customer Use, but prior to the date Illumina can supply the first TG Consumable under this Agreement are deemed to fall within the definition of Temporary Consumable, and (ii) that Illumina agrees
in writing may be used for Customer Use as a result of Illumina’s inability to supply TG Consumables, such written authorization not to be unreasonably withheld, are deemed to fall within the definition of Temporary Consumable. 

“Term” or “term of this Agreement” means the term of the Agreement as defined in Section 19.a.

 2. Applicability of Terms and Conditions. 
  

	 	a.	Exclusive Terms. This Agreement exclusively governs the ordering, purchase, supply, and use of Product, and its terms shall override any conflicting, amending
and/or additional terms contained in any purchase orders, invoices or similar documents, which are hereby rejected and shall be null and void. Failure of Illumina or Customer to object to any such conflicting, amending and/or additional terms shall
not constitute a waiver by Illumina or Customer, nor constitute acceptance by Illumina or Customer of such terms. The conditions and restrictions on use and other activities set forth in this Agreement are bargained for conditions of sale and,
therefore, control the sale of such Product and the rights in and to Products provided to Customer at purchase. This Agreement may be amended in writing only. For clarity, written amendments to this Agreement must be executed by officers of the
Parties. 

  

	 	b.	Consumables. The Consumables that may be purchased by Customer under this Agreement are set forth in Exhibit A, as may be amended in writing by the Parties;
provided that, Illumina will not unreasonably refuse to amend Exhibit A to add additional Consumables or remove existing Consumables. 

  

	 	c.	Instruments. The Illumina Hardware that may be purchased by Customer under this Agreement is set forth in Exhibit A. Unless otherwise set forth in Exhibit A, the
purchase price for Illumina Hardware will be agreed to in writing at the time of purchase. Unless expressly set forth otherwise in this Agreement, (i) notification of changes to Hardware and Software are not provided, and (ii) only
Illumina Hardware listed in Exhibit A, as may be amended from time-to-time in writing by the Parties, may be purchased under this Agreement; provided that, Illumina will not unreasonably refuse to amend Exhibit A to add additional Illumina Hardware
or remove existing Illumina Hardware. 

  

	 	d.	Temporary Consumables. This provision only applies to Temporary Consumables. In the event Illumina makes commercially available during the Term a TG version of a
Temporary Consumable (“TG Version”), Customer must, within [...***...] months after the commercial availability of the TG Version and receipt of notice from Illumina, cease ordering the Temporary Consumable for Customer Use.
No later than at expiration of the [...***...] month period, and only with respect to Consumables purchased for Customer Use, Illumina will supply Customer with only the TG Version of the applicable Consumable under the terms of this
Agreement. The Temporary Consumables shall, solely for the purposes of the Customer Use rights granted to Customer under Section 3, be considered to be TG Consumables until the expiration of the [...***...] month period described in the
preceding sentence. For the avoidance of doubt, after expiration of the [...***...] month period, Customer may use Non-TG Consumables (including former Temporary Consumables) only for Research Use. Except as expressly set forth otherwise in
writing by Illumina, notification of changes is not provided for Non-TG Consumables. The [...***...] for such new TG Version [...***...] for such TG Version. 

 

	 	e.	[...***...] Business Reviews. Customer and Illumina agree to have [...***...] business review meetings at mutually agreed upon times to
discuss [...***...] and anything else mutually agreed upon. The outcome of such business review meetings will not be binding unless documented in an amendment to this Agreement. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 3 

	 	f.	Minimum TG Consumable Purchases. Subject to the terms and conditions of this Agreement, Customer shall, purchase a minimum quantity of TG Consumables every
[...***...] calendar months during the Term beginning [...***...]. The minimum quantity of TG Consumables shall be the greater of (i) [...***...]% of the quantity of TG Consumables forecasted for such [...***...]
calendar month period as determined by Forecasts submitted by Customer that cover that time period, and (ii) $[...***...]. (x) If Customer does not meet its minimum purchase obligation, (A) [...***...] shall immediately
become null and void and of no further effect, and (B) all Product prices revert to the Base Price, regardless Customer’s volume of purchases. (y) In addition, if Customer does not meet its minimum purchase obligation (A) at any
time prior to the third anniversary of the Effective Date, the Term of this Agreement (Section 19.a) shall automatically convert to [...***...] years, and (B) at any time after the third anniversary of this Agreement, Illumina may in its
sole discretion terminate this Agreement early by providing [...***...] days prior written notice. 

 3. Rights
Accompanying Purchase.  
  

	 	a.	Consumables. Subject to the terms and conditions of this Agreement (including without limitation the restrictions in Section 5), Customer’s purchase of
TG Consumables, Temporary Consumables, and Non-TG Consumables under this Agreement confers upon Customer [...***...]. The Parties agree that the first sentence of this Section 3(a) is designed to and does alter the effect of the
exhaustion of patent rights that would otherwise result if the sale was made without restriction. Except as expressly stated in this Section 3(a) with respect to Core IP, no right or license under any Illumina Intellectual Property Rights is or
are granted, expressly, by implication, or by estoppel, to Customer under this Agreement. Any use of the Consumables recited in subparts (i) and (ii) herein outside the scope of rights expressly granted to Customer in this
Section 3(a) is a prohibited use and is a breach of this Agreement. Customer agrees that it will not use any such Consumable for a prohibited use. Product recited in subparts (i) and (ii) herein may be covered by one or more U.S. or
foreign patents. 

  

	 	b.	Illumina Hardware and Software. Subject to the terms and conditions of this Agreement (including without limitation the restrictions in Section 5),
Customer’s purchase of Illumina Hardware and Software under this Agreement confers upon Customer [...***...]. The Parties agree that the first sentence of this Section 3(b) is designed to and does alter the effect of the exhaustion
of patent rights that would otherwise result if the sale was made without restriction. Except as expressly stated in this Section with respect to Core IP, no right or license under any Illumina Intellectual Property Rights is or are granted,
expressly, by implication, or by estoppel, to Customer under this Agreement. Any use of the Illumina Hardware or Software outside the scope of the rights expressly granted to Customer in this Section 3(b) is a prohibited use and is a breach of
this Agreement. Customer agrees that it will not use any such Hardware for a prohibited use. Hardware may be covered by one or more U.S. or foreign patents. 

 

	 	c.	Existing Instruments. Subject to the terms and conditions of this Agreement, including without limitation, all restrictions and all Customer representations and
warranties hereunder with respect to Products, Customer (i), during the Term, has the right to use Existing Instruments for Customer Use, and (ii) during the Term and thereafter, has the right to use Existing Instruments for Research Use in
accordance with the scope of rights in Section 3b (Illumina Hardware). Customer agrees that Customer’s use of and disposition of the Existing Instruments is subject to the terms and conditions of this Agreement in addition to the original
terms and conditions under which the Existing Instruments were purchased from Illumina (the “Instrument Terms”). In the event of any conflict between the Instrument Terms and the terms and conditions of this Agreement with respect
to the Existing Instruments, the terms and conditions of this Agreement shall supersede and govern Customer’s use of and disposition of the Existing Instruments. Any use of the Existing Instruments outside of the scope of the rights expressly
granted to Customer in Section 3(b) is a prohibited use and is a breach of this Agreement. Customer agrees that it will not use any such Existing Instrument for a prohibited use. Existing Instruments may be covered by one or more U.S. or
foreign patents 

  

	 	d.	Software. All Software is licensed, not sold, to Customer, is non-transferable, non-sublicensable, and may be subject to additional terms found in the
Software’s end user license agreement (“EULA”). Subject to the terms and conditions of the EULA and the terms and conditions of this Agreement (including without limitation, all restrictions in Section 5 and all Customer
representations and warranties hereunder with respect to Products) Customer is expressly authorized to use Software provided by Illumina under this Agreement and provided by Illumina with Existing Instruments, as applicable, for Customer Use and
Research Use, as applicable, when used with the Consumables and Illumina Hardware. For clarity, Software may be used for Customer Use and Research Use when used with Consumables and Illumina Hardware for Customer Use and Research Use as authorized
by this Agreement. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 4 

	 	e.	[...***...] Agreement. Within [...***...] of the Effective Date, the Parties shall negotiate and execute a [...***...] Agreement. Subject to
the terms and conditions of this Agreement, Customer and Illumina agree to comply with the terms of the [...***...] Agreement during the Term (as defined herein). The Parties agree that the terms and conditions of the [...***...]
Agreement may be amended from time-to-time by representatives of the Parties’ respective [...***...] departments; provided that, such amendments are done in writing and signed by such representatives. 

 

	 	f.	Service Contract. During the Term, Illumina shall offer and Customer shall purchase and maintain a Service Contract for all Illumina Hardware that Customer owns
or uses. Existing service contracts that Customer has will terminate on the Effective Date and Illumina shall issue Customer a credit for any unused portion. Subject to the terms of the Service Contract and the terms and conditions of this
Agreement, Illumina will, [...***...]: 

  

	 	i.	[...***...] Spare Parts. Illumina will, [...***...] spare parts for the Illumina Hardware used at [...***...]. Such spare parts to be kept in
stock shall include [...***...] for [...***...] HiSeq and other Illumina Hardware and Software. [...***...] Customer and Illumina agree [...***...] the terms and conditions of Illumina’s spare parts contract (Appendix
II) will solely govern all matters pertaining to such spare parts. 

  

	 	ii.	[...***...]. 

  

	 	iii.	Qualification Services. Installation Qualification, Operational Qualification and Instrument Performance Verification are available upon the Customer’s
request at any time during the term of the Agreement. The Base Price for such services, as of the Effective Date, are set forth in Exhibit A-1. The descriptions of these services are listed below: 

 

	 	•	 	 Installation Qualification: documentation that facilities in which the instrument has been installed are in accordance with requirements and safety
regulations of the original manufacturer. 

  

	 	•	 	 Operational Qualification: evaluates the correct functionality of the equipment under test by examining and quantifying the specifications after
installation. 

  

	 	•	 	 Instrument Performance Verification: ensures the accuracy of the instrument after a major service event or replacement of specific modules.

  

	 	•	 	 Feedback from the Customer on any of these procedures will be considered and may be incorporated into future releases. Customer and Illumina will agree
upon the format for such feedback. 

 4. Additional Rights; Application Specific IP. 

 

	 	a.	Additional Rights. (a) Customer’s intended use of Products for Customer Use or Research Use during the Term may require that it obtain from third
parties or from Illumina (or its Affiliates) additional rights or licenses above and beyond the rights under Core IP conferred in Section 3, including without limitation, rights to Application Specific IP, Affiliate Application Specific IP, and
Third Party IP. Illumina does not guarantee or warrant that Customer’s intended use of Product will not infringe Application Specific IP, Affiliate Application Specific IP, or Third Party IP. 

(b) Customer, not Illumina, is responsible for identifying and ensuring that it has rights or licenses to all Intellectual Property,
including without limitation, Application Specific IP, Third Party IP, and Affiliate Application Specific IP that are required for Customer to use the Products as intended by Customer for Customer Use and Research Use without infringing such third
party and Illumina Intellectual Property Rights, including the Intellectual Property Rights of Illumina’s Affiliates. Customer will obtain required rights to Third Party IP from a third party or required rights to Application Specific IP from
Illumina or Affiliate Application Specific IP from Illumina’s Affiliate, or Customer will discontinue use of Products in a manner that infringes Third Party IP, Affiliate Application Specific IP, or Application Specific IP, as applicable. .

 (c) Notwithstanding the foregoing, any future grant by Illumina to Customer of rights to Application Specific IP or Affiliate
Application Specific IP will be [...***...] granted, if at all, under a separate written agreement. 
 (d) Customer’s
breach of any term or condition of this Section 4(a) is a breach of the Agreement. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 5 

 5. Limitations on Use. 

 

	 	a.	Limitations on Use. 

  

	 	i.	Customer agrees: (1) to use each Consumable only one time, (2) not to use non-Illumina reagents with Illumina Hardware, (3) to use the Products
only within the scope of the rights expressly granted to Customer in Section 3 (Rights Accompanying Purchase), (4) to use the TG Consumables and Temporary Consumables only for Customer Use and Research Use, (5) to use the Non-TG
Consumables only for Research Use, (6) to use Hardware and Software only for Customer Use when Hardware and Software is used with TG Consumables and Temporary Consumables, and (7) to only use Products in Customer’s Facilities. The
limitations in (1)-(2) do not apply if the Specifications or Documentation for the applicable Consumable expressly states otherwise. [...***...]. 

 

	 	ii.	Customer agrees it will not, and it will not authorize any third party to, engage in any of the following activities: (1) disassemble, reverse-engineer,
reverse-compile, or reverse-assemble the Product, (2) separate, extract, or isolate components of Product or subject Product or components thereof to any analysis not authorized in the Specifications or Documentation, (3) gain access to or
attempt to determine the methods of operation of the Product, (4) grant a sub-license to any rights received hereunder, including to grant a sublicense to any Software or to any third-party software, or (5) transfer any Software to a
third-party (including a Customer Affiliate). [...***...]. 

  

	 	iii.	Customer agrees it will not (1) use the Products for any use outside of Customer Use or Research Use, (2) use the Products in any manner that
infringes, or is within the scope of, Application Specific IP including Affiliate Application Specific IP, unless it has received prior express written permission from Illumina under a separate written agreement or amendment to this Agreement to use
the Products in a manner addressed in (1) or (2). 

  

	 	b.	Illumina Proprietary Information. Customer agrees that it shall only use the Illumina proprietary sequences (e.g., IllumiCode/Universal Sequences,
Oligonucleotide Capture Sequences, adapter sequences, and such other proprietary sequences as Illumina may identify from time to time) with the Products. Customer agrees that the contents of and methods of operation of the Products are proprietary
to Illumina and/or its Affiliates and contain or embody trade secrets of Illumina and/or its Affiliates. 

  

	 	c.	Unauthorized Uses. Customer agrees that (i) the activities described in Section 5a.i and Section 5a.ii (Limitations on Use) (A) are, without
limitation, part of the bargained for conditions of sale of the Products, (B) are not included within the Customer Use or the Research Use or otherwise within the rights expressly provided to Customer pursuant to Section 3 (Rights
Accompanying Purchase), and (C) each, including restrictions against the use of the Product to perform any of those activities, is an unauthorized use, may infringe Illumina Intellectual Property Rights, and is part of the bargained for
conditions of sale of the Products; and (ii) any violation of or breach of any provision of this Section 5 or any use of the Products outside the scope of the rights expressly granted to Customer in Section 3 (Rights Accompanying
Purchase) is a breach of this Agreement. 

 6. Forecasts for TG Consumables; Initial Shipment Date. Please refer to the
example in Exhibit B when reading this Section. 
  

	 	a.	Forecast. Customer shall, [...***...] being a “Forecast Due Date”), provide a written forecast detailing the quantity of TG Consumables,
on a TG Consumable-by-TG Consumable basis, that Customer requires during [...***...] following that Forecast Due Date (each a “Forecast”). For clarity, each Forecast starts with the [...***...] Forecast Due Date. The
general form of the Forecast along with an example of how forecasting works and when Purchase Orders (defined below) are to be provided is found in Exhibit B. The first Forecast is attached to this Agreement as Attachment I. For
the avoidance of doubt, Illumina has no obligation to provide TG Consumables during any Forecast period ([...***...]) if Customer has not provided a Forecast for that period as required by the terms of this Agreement, including by Forecast Due
Date. 

  

	 	i.	One Forecast per Calendar Month Only. Customer may only provide one Forecast per [...***...]. If Customer provides more than one Forecast
in any [...***...] Illumina may elect to use any of the Forecasts provided in that [...***...] and the one used by Illumina shall be binding on the Customer. Customer must provide a [...***...] Forecast. If Customer does not
provide a Forecast by the Forecast Due Date then Illumina, in its sole discretion, may consider the previously provided Forecast as the Forecast that is then due. 

 

	 	ii.	Initial Shipment Date. Notwithstanding anything in this Agreement to the contrary, Illumina makes no guarantee that it can ship TG Consumables earlier than
[...***...] from the Effective Date. For clarity, each Product has a unique catalog number (e.g., TG Consumables have a different catalog number than its corresponding Non-TG Consumable) and therefore Customer will only be required to pay the
price associated with the TG Consumable when Customer is purchasing a TG Consumable. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 6 

	 	b.	Binding Commitments; Flexibility. The [...***...] provided under this Agreement is a binding commitment by Customer to take receipt of and pay for that
quantity and type of TG Consumables found in such [...***...] (the “Binding Consumable [...***...]”); provided that, the quantity of each TG Consumable (on a TG Consumable-by-TG Consumable basis) to be delivered in such
[...***...] may vary from the quantity of each TG Consumable (on a TG Consumable-by-TG Consumable basis) that were forecasted to be required in the same [...***...] as found in prior Forecast ([...***...] of that prior Forecast)
only by up to [...***...]%. 

  

	 	c.	New TG Consumables. Any TG Consumables that are newly added to this Agreement shall initially be forecasted so that the quantities for purchase and delivery in
the first [...***...] are [...***...]. 

  

	 	d.	Temporary Consumables Forecast ([...***...]). Customer may, in its discretion, provide a forecast of its expected requirements for Temporary
Consumables during [...***...] of the Agreement. 

  

	7.	Pricing; Purchase Orders. 

  

	 	a.	Pricing. Customer shall pay the Net Price for Product. Unless expressly stated otherwise in this Agreement, (i) all prices are in USD, (ii) all
payments must be made in USD. 

  

	 	b.	Purchase Orders. 

  

	 	i.	Purchase Orders and Acceptance. Customer shall order Product using written purchase orders (“Purchase Order(s)”). Purchase Orders shall state,
at a minimum, the Illumina part number, the Illumina provided quote number (or other reference provided by Illumina), the quantity ordered, price, requested delivery date, and address for delivery. All Purchase Orders shall be sent to the attention
of Illumina Customer Solutions or to any other person or department designated by Illumina in writing. Acceptance of a Purchase Order occurs when Illumina provides Customer a Sales Order Confirmation (“Order Confirmation”). Purchase
Orders submitted in accordance with this Agreement will not be unreasonably rejected by Illumina. 

  

	 	ii.	TG Consumable Purchase Orders. The first Purchase Order for TG Consumables must be provided with the first Forecast. Subsequent Purchase Orders for TG
Consumables must be provided on the Forecast Due Date and must be for a quantity of and type of TG-Consumables as found in the Binding Consumable [...***...]. For the avoidance of doubt, Illumina has no obligation to provide TG Consumables
found in the Binding Consumable [...***...] if Customer has not provided a Purchase Order by the Forecast Due Date and the failure to provide a Purchase Order will not relieve Customer of any of its obligations arising from Forecasts and such
failure may, among other things, result in a delay in delivery of Products to Customer. Each Purchase Order for TG Consumables must include a ship schedule, to be agreed to between Illumina and Customer, that details the quantity of and type of TG
Consumables (on a TG Consumable-by-TG Consumable basis) that Customer requires in each calendar month that is covered by the Purchase Order (“Ship Schedule”). Illumina has no obligation to accept Purchase Orders that contain TG
Consumables or quantities of TG Consumables that exceed what was forecasted by Customer (“Excess Orders”); provided that, Illumina [...***...] reject such Excess Orders that do not [...***...]% of the quantity forecasted
unless Illumina agreeing to supply such excess quantity of TG Consumables (i) requires Illumina exercising anything [...***...], or (ii) would impair Illumina’s ability to honor supply commitments to other customers. Such
additional quantities of TG Consumables must be ordered by using Additional Purchase Orders (set forth below). 

  

	 	iii.	Additional Purchase Orders for TG Consumables. Illumina will, in its reasonable discretion, accept additional Purchase Orders for additional quantities of TG
Consumables that were not within a given Forecast (“Additional Purchase Orders”). Ship dates and quantities of TG Consumables on any Additional Purchase Orders will be mutually agreed to in writing. 

 

	 	c.	Payment Instead of Taking TG Consumable. Illumina reserves the right to invoice Customer for [...***...]% of the purchase price of any TG Consumables
that Customer has a binding commitment to purchase under this Agreement (whether under a Forecast or a Purchase Order), but that Customer has not provided a Purchase Order for, or for which Customer is attempting to cancel the order or delivery for.
If there is no applicable Purchase Order, the purchase price shall be the purchase price that would have applied under this Agreement had Customer placed a Purchase Order for such Consumables. [...***...] failure to purchase Consumables under
a binding commitment under this Agreement (whether under Forecast or a Purchase Order). 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 7 

	 	d.	Inability to Supply due to Force Majeure; [...***...]. 

  

	 	i.	Inability to Supply due to Force Majeure. Subject to the terms and conditions of this Agreement, in the event Illumina is unable to perform its obligations under
this Agreement due to a Force Majeure Event (defined in Section 22.j), [...***...]. 

  

	 	ii.	[...***...]. Subject to the terms and conditions of this Agreement, Illumina shall promptly notify Customer if Illumina reasonably believes that Illumina
will not have sufficient capacity to supply Customer with the quantity of Products set forth in Customer’s most recent Forecast. In the event such capacity constraint exists, Illumina shall [...***...]. 

 

	 	e.	On Time Deliveries (Applicable to TG Consumables Only). The “Promised Delivery Date” for a TG Consumable shipped from Illumina’s facilities
located in (i) the same country as Customer’s Facility shall be the date that is [...***...], and (ii) a different country than Customer’s Facility shall be the date that is [...***...] after the shipment date for
such TG Consumable stated in the Order Confirmation; provided that, Customer and Illumina agree that the shipment date found in the Order Confirmation may be adjusted by mutual agreement of representatives of the Parties, such mutual agreement may
be made via email, fax, or in a written and signed agreement. “[...***...]” means [...***...] and no later than [...***...] after the [...***...]. Customer shall earn a credit in an amount equal to
[...***...]% of the Net Price for each [...***...] that does not meet [...***...]; provided that, [...***...]. This Section 7e provides Customer’s [...***...] in a timely manner under this Agreement. For
the avoidance of doubt [...***...]. Illumina shall provide Customer with [...***...]. 

  

	 	i.	Reporting Late Deliveries. Within [...***...] of the end of each calendar quarter of this Agreement and within [...***...] of termination or
expiration of this Agreement (the “Due Date”), Customer will submit a written report to Illumina detailing [...***...], and in the case of termination or expiration of this Agreement since the end of the last reporting period,
for which Customer is seeking [...***...] pursuant to Section 7e (the “Late Delivery Report”). The Late Delivery Report shall be sent in writing to: customerservice@illumina.com. The Late Delivery Report must include the following:
[...***...]. 

  

	 	f.	[...***...]. Illumina will review the Late Delivery Report. In the event of any discrepancies the Parties will negotiate in good-faith to resolve the
matter. Illumina will [...***...] within [...***...] of the Late Delivery Report; provided that, [...***...]. 

 8. Invoices; Payment; Taxes.  
  

	 	a.	Invoices and Payment. Illumina shall issue invoices upon shipment of Products. Invoices shall be sent to Customer’s accounts payable department, or any
other address designated by Customer in writing. All payments by Customer on such invoices are due within [...***...] after the date of the invoice. Any amounts not paid when due under this Agreement (other than amounts disputed by Customer in
good-faith) will accrue interest at the rate of [...***...]% per month, or the maximum amount allowed by law, if lower. In the event that any payment is not made within [...***...] after receiving notice of the delinquency, Customer will
be in breach of this Agreement and Illumina shall have the right to take any action allowed in law and in equity in addition to any rights under this Agreement, including without limitation, revoke the rights conferred and/or licenses given
hereunder and suspend performance, including shipment, until all payments are made current. Customer shall pay for all costs (including reasonable attorneys’ fees) incurred by Illumina in connection with the collection of late payments. Each
Purchase Order is a separate, independent transaction under this Agreement, and Customer has no right of set-off against other Purchase Orders or other transactions with Illumina. Customer agrees to pay for Products supplied hereunder in accordance
with the terms and conditions of this Agreement. [...***...] Upon such Illumina Hardware meeting such testing criteria, Customer shall sign a document indicating [...***...] of such Illumina Hardware. Customer’s failure to sign such
document when such Illumina Hardware meets [...***...] shall be a material breach of this Agreement by Customer. Payments made by Customer on invoices for Illumina Hardware that are installed by Illumina are due the earlier of
(i) [...***...] or (ii) [...***...] 

  

	 	b.	Taxes. All prices and other amounts payable to Illumina hereunder are exclusive of and are payable without deduction for taxes, GST, VAT, customs duties, tariffs
or charges now or hereafter claimed or imposed by any governmental authority upon the sale of the Product, all of which will be added to the purchase price or subsequently invoiced to the Customer. With respect to New Zealand Customers only,
Customer and Illumina agree that subsection 8(4) Goods and Services Tax Act 1985 does not apply. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 8 

 9. Shipping Terms; Title and Risk of Loss. Illumina agrees that Customer may choose the carrier for
shipments. Unless otherwise agreed upon in writing, all shipments are made DAP (Incoterms 2010) at Customer’s address on the Purchase Order and Customer is responsible for freight and insurance which will be added to the invoice and paid by
Customer, except that all shipments to member countries of the E.U. are made DDP (Incoterms 2010) at Customer’s address on the Purchase Order. In all cases title (except for Software and third-party software) and risk of loss transfers to
Customer when Product is delivered to such address. 
 10. Consumable Shelf-life for TG Consumables. The TG Consumables shall have no
less than [...***...] shelf life at the time of shipment. Shelf-life will be pre-printed on the TG Consumable packaging. 
 11.
Single Lot Shipments/ Kit Lot Testing for TG Consumables.  
  

	 	a.	Single Lot Shipments. Illumina shall ensure (i) each shipment of a given TG Consumable includes only such TG Consumable manufactured from the same lot,
(ii) each lot of TG Consumables and lot of kits containing TG Consumables is assigned a unique manufacturing lot number, which is displayed on each component, and (iii) each kit in a kit lot is comprised of component of TG Consumables
manufactured from the same lots. 

  

	 	b.	Kit Lot Testing. Illumina shall test each component reagent that comprises a given TG Consumable together with the other component reagents of that TG Consumable
to ensure their functionality, unless sufficient data are available to demonstrate that a given component reagent, or component reagents, if quality tested independently, does not affect performance of the TG Consumable. 

 

	 	c.	Certificates of Analysis. Illumina shall, once made available for all TG Consumables as part of Illumina’s standard commercial offering for TG Consumables,
provide a Certificate of Analysis for each lot of TG Consumables sold to Customer under this Agreement. 

 12. Changes to
Certain Product; Discontinuations 
  

	 	a.	[...***...]. In cases where [...***...] purchased under this Agreement is being [...***...] out or there is a [...***...] of such
[...***...] that results in a change to [...***...], Illumina shall make [...***...] to provide Customer with a [...***...] advance notice [...***...] to the [...***...]. Illumina will notify Customer of the
[...***...] options available should Customer desire to replace such [...***...]. This change notice will not apply to changes necessitated by causes beyond Illumina’s control or for changes necessary for safety which changes shall
be communicated to Customer as soon as practicable after Illumina learns of the need for the changes through Illumina’s normal communication channels for changes. 

 

	 	b.	Discontinued/Changed TG Consumables. TG Consumables will not be manufactured in their current configurations indefinitely as a result of product life cycle or
other business considerations. Accordingly, a given TG Consumable may be phased out of production and no longer available and/or there may be a new, reconfigured, or repackaged version of a TG Consumable that embodies a material change to form, fit
or function of such TG Consumable (such discontinued or materially changed Consumable is referred to as a “Discontinued Consumable”). Any product or combination of products that is intended by Illumina to replace such Discontinued
Consumable shall be referred to as a “Substitute Consumable.” In some instances a Substitute Consumable may differ from the Discontinued Consumable through changes in one or more components that comprised the Discontinued Consumable
(“Changed Components”). In other instances the Substitute Consumable may represent a complete change from the Discontinued Consumable (“Complete Change”). In the case of a Discontinued Consumable that will have
Changed Components, Illumina will use [...***...] but no later than [...***...] prior to the date that the Discontinued Consumable will no longer be available for purchase. Illumina will provide [...***...]. In the case of a
Discontinued Consumable that will have a Complete Change, Illumina will make the Substitute Consumable available for purchase by Customer [...***...] no later than [...***...] prior to the date that the Discontinued Consumable will no
longer be available for purchase. Illumina will provide [...***...] free of charge [...***...]. Once a Discontinued Consumable is no longer available for purchase (either in the instance of a Complete Change or Changed Component), the
Substitute Consumable will automatically be added to this Agreement as a Consumable and the Discontinued Consumable will be removed. The price for a Substitute Consumable will be [...***...] for the Substitute Consumable. Use of Substitute
Consumables shall be subject to the terms and conditions of this Agreement. Notwithstanding anything to the contrary in this Agreement, if Illumina offers a product or combination of products that, [...***...] Illumina may require Customer to
begin purchasing such product in lieu of the Product and the Parties will work together [...***...] to coordinate such transition and to modify the terms of this Agreement to reflect such change. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 9 

 13. Regulatory; Quality Audits. 

 

	 	a.	Research Use. Customer acknowledges that, unless expressly stated otherwise in writing by Illumina, the Products have not been subjected to regulatory review or
approved or cleared by the United States Food and Drug Administration or any other regulatory entity whether foreign or domestic, or otherwise reviewed, cleared or approved under any statute, law, rule or regulation for any purpose, whether
research, commercial, diagnostic or otherwise. The Products are labeled For Research Use Only. Illumina does not make any representation, warranty or covenant that pertains in any way to the regulatory status of the Products and Customer’s
intended use for Customer Use. 

  

	 	b.	Regulatory Approvals. Customer, and not Illumina, is responsible for obtaining any and all regulatory approvals, licenses, and/or certifications necessary for
Customer to use the Products as intended by Customer, including without limitation, for Customer Use or Research Use (“Regulatory Approvals”). Customer will ensure it has any regulatory approvals that are necessary for
Customer’s intended use of the Products. Accordingly, Customer agrees to (i) diligently investigate and identify which Regulatory Approvals apply to Customer’s use of the Products, (ii) obtain and maintain all Regulatory
Approvals throughout the time that Customer uses the Products, and (iii) use the Products in compliance with all applicable laws and regulations. Customer agrees to promptly disclose to Illumina any communication that it receives from a
government body, agency, or other regulatory or accrediting body pertaining to the Products or Customer’s use of the Products. 

  

	 	c.	Quality Audits. Illumina agrees to allow Customer to audit Illumina’s operations that pertain to TG Consumables, upon [...***...] prior written
notice, during normal business hours, no more often than [...***...], and at [...***...], in order to satisfy its obligations under applicable law. The locations, times, dates, scope, and goals for such audits will be mutually agreed
upon in writing between the Parties. Customer shall sign Illumina’s confidentiality agreement, if requested by Illumina, prior to conducting such audit. 

 14. Limitation of Liability. 
 EXCEPT WITH RESPECT TO ANY CLAIM OR LIABILITY ARISING OUT OF
A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, TO THE EXTENT PERMITTED BY LAW, IN NO EVENT SHALL EITHER PARTY OR THEIR RESPECTIVE AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY THIRD PARTY FOR COSTS OF PROCUREMENT OF
SUBSTITUTE PRODUCTS OR SERVICES, LOST PROFITS, DATA OR BUSINESS, OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH, WITHOUT LIMITATION, THE PURCHASE OR SALE OF
THE PRODUCTS, THEIR USE, SUCH PARTY’S PERFORMANCE HEREUNDER OR ANY OF THESE TERMS AND CONDITIONS, HOWEVER ARISING OR CAUSED AND ON ANY THEORY OF LIABILITY (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE).

 EXCEPT WITH RESPECT TO THE PARTY’S INDEMNIFICATION OBLIGATIONS AND ANY CLAIM OR LIABILITY ARISING OUT OF A PARTY’S BREACH OF ITS
CONFIDENTIALITY OBLIGATIONS HEREUNDER, EACH PARTY’S TOTAL AND CUMULATIVE LIABILITY ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE, SHALL IN NO EVENT EXCEED AN
AMOUNT EQUAL TO [...***...]. 
 THE LIMITATION OF LIABILITY IN THIS SECTION SHALL APPLY EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF
SUCH DAMAGES, AND NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. 
 NOTWITHSTANDING ANYTHING IN THIS AGREEMENT,
INCLUDING, WITHOUT LIMITATION, THIS SECTION 14, TO THE CONTRARY, NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY’S LIABILITY TO THE OTHER PARTY OR ITS AFFILIATES FOR [...***...]. 

15. Limited Warranties. TO THE EXTENT PERMITTED BY LAW AND EXCEPT FOR THE EXPRESS LIMITED PRODUCT WARRANTIES SET FORTH IN SECTION 18 OF THIS
AGREEMENT, ILLUMINA MAKES NO (AND EXPRESSLY DISCLAIMS ALL) WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE PRODUCTS OR ANY SERVICES PROVIDED IN CONNECTION WITH THIS AGREEMENT, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTY OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR ARISING FROM COURSE OF PERFORMANCE, DEALING, USAGE OR TRADE. WITHOUT LIMITING THE GENERALITY OF THE FOREGOING, ILLUMINA MAKES NO CLAIM, REPRESENTATION, OR WARRANTY OF ANY KIND AS
TO THE UTILITY OF THE PRODUCTS FOR CUSTOMER’S INTENDED USES. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 10 

	16.	Confidentiality. 

  

	 	a.	Confidential Information. The Parties acknowledge that a Party (the “Recipient Party”) may have access to confidential or proprietary
information (“Confidential Information”) of the other Party (the “Disclosing Party”) under this Agreement. In order to be protected as Confidential Information, information must be disclosed with a confidential or
other similar proprietary legend and in the case of orally or visually disclosed Confidential Information, the Disclosing Party shall notify the Recipient Party of its confidential nature at the time of disclosure and provide a written summary that
is marked with a confidential or other similar proprietary legend to the Recipient Party within [...***...] (email acceptable). Confidential Information may include, but shall not be limited to, inventions, designs, formulas, algorithms, trade
secrets, know-how, customer lists, demand forecasts, cost and pricing information, business and marketing plans, and other business, regulatory, manufacturing and financial information. This Agreement, including its terms and conditions is
Confidential Information. During the term of this Agreement or [...***...], whichever is longer, the Recipient Party shall hold the Disclosing Party’s Confidential Information in confidence using at least the degree of care that is used
by the Recipient Party with respect to its own Confidential Information, but no less than reasonable care. The Recipient Party shall disclose the Confidential Information of the Disclosing Party solely on a need to know basis to its employees,
contractors, officers, directors, representatives, and Affiliates under written nondisclosure and restricted use terms consistent with this Agreement. The Recipient Party shall not use the Disclosing Party’s Confidential Information for any
purpose other than exercising its rights and fulfilling its obligations under this Agreement. The Confidential Information shall at all times remains the property of the Disclosing Party. Upon the termination or expiration of this Agreement, the
Recipient Party shall, upon written request of the Disclosing Party, return to the Disclosing Party or destroy the Confidential Information of the Disclosing Party. Notwithstanding the foregoing, the Recipient Party may maintain one copy of the
Disclosing Party’s Confidential Information to be retained by the Recipient Party’s Legal Department for archival purposes only. 

  

	 	b.	Exceptions. Notwithstanding any provision contained in this Agreement to the contrary, neither Party shall be required to maintain in confidence or be restricted
in its use of any of the following: (i) information that, at the time of disclosure to the Recipient Party, is in the public domain through no breach of this Agreement or another obligation of confidentiality owed to the Disclosing Party or its
Affiliates by the Receiving Party; (ii) information that, after disclosure hereunder, becomes part of the public domain by publication or otherwise, except by breach of this Agreement or breach of another obligation of confidentiality owed to
the Disclosing Party or Affiliate by the Receiving Party; (iii) information that was in the Recipient Party’s or its Affiliate’s possession at the time of disclosure hereunder by the Disclosing Party unless subject to an obligation of
confidentiality or restricted use owed to the Disclosing Party or its Affiliate; (iv) information that is independently developed by or for the Recipient Party or its Affiliates without use of or reliance on Confidential Information of the
Disclosing Party; or (v) information that the Recipient Party receives from a third party where Recipient Party reasonably believes such third party was under no obligation of confidentiality to the Disclosing Party or its Affiliate with
respect to such information. 

  

	 	c.	Disclosures Required by Law. The Recipient Party may disclose Confidential Information of the Disclosing Party as required by court order, operation of law, or
government regulation, including in connection with submissions to regulatory authorities with respect to the Products; provided that, the Recipient Party promptly notifies the Disclosing Party of the specifics of such requirement prior to the
actual disclosure, or promptly thereafter if prior disclosure is impractical under the circumstances, uses diligent efforts to limit the scope of such disclosure or obtain confidential treatment of the Confidential Information if available, and
allows the Disclosing Party to participate in the process undertaken to protect the confidentiality of the Disclosing Party’s Confidential Information including, without limitation, cooperating with the Disclosing Party in order to comply with
the requirements of such order, law, or regulation in a manner that discloses the least amount necessary, if any, of the Confidential Information of the Disclosing Party. 

 

	 	d.	Injunctive Relief. Each Party acknowledges that any use or disclosure of the other Party’s Confidential Information other than in accordance with this
Agreement may cause irreparable damage to the other Party. Therefore, in the event of any such use or disclosure or threatened use or threatened disclosure of the Confidential Information of either Party hereto, the non-breaching Party shall be
entitled, in addition to all other rights and remedies available at law or in equity, to seek injunctive relief against the breach or threatened breach of any obligations under this Section. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 11 

	 	e.	Disclosure of Agreement. Except as expressly provided otherwise in this Agreement, neither Party may disclose this Agreement, the terms of this Agreement,
including any financial terms thereof, and the subject matter of this Agreement to any third party without the prior written consent of the other Party, which consent shall not be unreasonably withheld. Notwithstanding anything in this Agreement to
the contrary, each Party acknowledges and agrees that either Party may, to the extent required by applicable healthcare disclosure law, disclose this Agreement, its terms, its subject matter, including financial terms (e.g, Illumina’s
compliance with the Sunshine Act). 

  

	17.	Indemnity; Insurance. 

  

	 	a.	Infringement. Subject to the terms and conditions of this Agreement, including without limitation, the Exclusions to Indemnification Obligation (Section 17(b)
below), Indemnification by Customer (Section 17(c) below), Conditions of Indemnification Obligation (Section 17(e) below), and Customer’s obligations to obtain rights to Third Party IP pursuant to Section 4 (Additional Rights), Illumina shall
(i) defend, indemnify and hold harmless Customer, its Affiliates, and their respective officers, directors, representatives and employees (each a “Customer Indemnitee”), against any claim or action brought by a third-party (who
is not an Affiliate of Customer or an Affiliate of Illumina) as a result of the (A) Products when used for Research Use, and (B) Illumina Hardware, Software, TG Consumables, and Temporary Consumables when used for Customer Use, in
accordance with the terms and conditions of this Agreement, infringing the valid and enforceable Intellectual Property Rights of a third party (who is not an Affiliate of Customer or an Affiliate of Illumina) (“Illumina Infringement
Claim”), and (ii) pay all settlements entered into, and all final judgments and costs (including reasonable attorneys’ fees) awarded against such Customer Indemnitee in connection with such Illumina Infringement Claim. If the
Products or any part thereof, become, or in Illumina’s opinion may become, the subject of an Illumina Infringement Claim against Illumina (including its Affiliates) or Customer, Illumina shall have the right, at its option, to (A) procure
for Customer the right to continue using such Products, (B) modify or replace such Products with substantially equivalent noninfringing substitutes, or (C) require the return of such Products that are or may become the subject of an
Illumina Infringement Claim and terminate the rights, license, and any other permissions given hereunder with respect thereto and refund to Customer the depreciated value (as shown in Customer’s official records) of the returned Product at the
time of such required return; provided that, no refund will be given for used-up or expired Consumables. This Section states the entire liability of Illumina for any infringement of third party Intellectual Property Rights. 

 

	 	b.	Exclusions to Indemnification Obligation. Illumina shall have no obligation under Section 17(a), including to defend, indemnify or hold harmless Customer or
pay any settlements with respect to any Illumina Infringement Claim, to the extent such Illumina Infringement Claim arises from: (i) the use of the Products in any manner or for any purpose outside the scope of the rights, license(s), or
permissions granted by Illumina to Customer with respect to the Products under Section 3 (Rights Accompanying Purchase), (ii) the use of the Products in any manner or for any purpose not in accordance with the Specifications or
Documentation, (iii) the use of the Products in combination with any other products, materials, or services not supplied by Illumina, (iv) the use of the Products to perform any assay or other process not supplied by Illumina,
(v) Illumina’s compliance with specifications or instructions for such Products furnished to Illumina by Customer or by a third party on behalf of Customer (e.g., custom goods), (vi) the use of the Products in any manner or for any
purpose that requires rights to Application Specific IP, Affiliate Application Specific IP [...***...] or (vii) Customer’s breach of any term or condition, including breach of a representation or warranty, made hereunder or included
in this Agreement, wherein any use specified in (i), (ii), (iii) (iv) or (vi) is a use performed by Customer, its Affiliate, or a party to whom Customer or its Affiliate transfers Product (regardless of whether transfer is permitted
under this Agreement) (each of (i) – (vii), are referred to as an “Excluded Claim”). 

  

	 	c.	 Indemnification by Customer. Subject to the terms and conditions of this Agreement, including without limitation the Conditions of
Indemnification provision below (Section 17e), Customer shall defend, indemnify and hold harmless Illumina, its Affiliates, their collaborators and development partners that contributed to the development of the Products, and their respective
officers, directors, representatives and employees (“Illumina Indemnitee(s)”), against any third party claims, causes of action, and all liabilities, damages, fines, penalties, causes of action, and losses of any and every kind
(“Claim”), including without limitation, claims relating to or arising out of personal injury or death, and claims relating to or arising out of infringement of a third party’s Intellectual Property Rights, to the extent a
Claim results from, relates to, or arises out of (i) Customer’s breach of any term or condition, including breach of a representation or warranty made hereunder or included in this Agreement, (ii) Customer’s use of the

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 12 

	 	
Product outside of the scope of the rights, license(s), and permissions expressly granted to Customer with respect to such Product pursuant to Section 3 (Rights Accompanying Purchase),
(iii) Customer’s use of a Product not in accordance with its Documentation or Specifications, (iv) any of the activities in (i) through (vii) of Excluded Claim, (v) Customer’s failure to obtain and maintain
Regulatory Approvals, or (vi) any unauthorized use of the Products in any manner, or for any purpose that requires rights to Affiliate Application Specific IP, Application Specific IP, or Third Party IP. 

 

	 	d.	Further Indemnification by Illumina. In addition to and without limiting the obligations set forth under Section 17a and subject to the terms and conditions
of this Agreement, including without limitation, the Conditions of Indemnification provision below (Section 17e), Illumina shall defend, indemnify and hold harmless each Customer Indemnitee against any Claims relating to or arising out of personal
injury or death that results from Customer’s use of a defective Product purchased by Customer under this Agreement (“Personal Injuries”), specifically excluding any Personal Injuries (i) arising from or in any way relating
to any actions (or inactions) taken by individuals or healthcare providers (e.g., persons, patients, physicians, healthcare providers) who receive results from Customer’s use of Products and (ii) that could have been avoided by Customer
using reasonable measures.. 

  

	 	e.	Conditions of Indemnification. The Parties’ indemnification obligations under this Section 17 are subject to the Party seeking indemnification
(i) notifying the other, indemnifying Party promptly in writing of an Illumina Infringement Claim or Third Party Claim, as the case may be, (provided that a delay in providing shall not relieve the other Party of its indemnification obligations
except to the extent it is prejudiced by such delay) (ii) giving indemnifying Party exclusive control and authority over the defense of such Claim, (iii) not admitting infringement of any Intellectual Property Right without prior written
consent of the indemnifying Party, (iv) not entering into any settlement or compromise of any such action without the indemnifying Party’s prior written consent not to be unreasonably withheld, conditioned, or delayed, and
(v) providing all reasonable assistance to the indemnifying Party that the indemnifying Party requests and ensuring that its officers, directors, representatives and employees and other indemnitees likewise provide assistance (provided that
indemnifying Party reimburses the indemnified Party(ies) for its/their reasonable out-of-pocket expenses incurred in providing such assistance). An indemnifying Party will not enter into or otherwise consent to an adverse judgment or order, or make
any admission as to liability or fault that would adversely affect the indemnified Party, or settle a dispute without the prior written consent of the indemnified Party, which consent not to be unreasonably withheld, conditioned, or delayed.

  

	 	f.	Third-Party Goods. Notwithstanding anything in this Agreement to the contrary, Illumina shall have no indemnification obligations with respect to any goods or
software originating from a third party and supplied to Customer under this Agreement. Third-party goods are those that are labeled or branded with a third-party’s name. Customer’s sole right to indemnification with respect to such third
party goods or software shall be pursuant to the original manufacturer’s or licensor’s indemnity, if any, to Customer, to the extent provided by the original manufacturer or licensor. 

 

	 	g.	Insurance. Customer shall obtain and maintain insurance coverage as follows: (i) a policy for liability (including professional and errors &
omissions) in the amount of no less than [...***...] per occurrence, and (ii) separately a policy for commercial general liability and public liability insurance (that excludes product liability) in the amount of no less than
[...***...], in the case of each of (i) and (ii) to protect the Illumina Indemnitees under the indemnification provided hereunder. Illumina shall be an additional insured on Customer’s insurance policy or policies and, upon
request, Illumina shall be provided appropriate certificates of insurance. Such policies shall provide a waiver of subrogation against Illumina as an additional insured and contain no cross-liability exclusion. Customer agrees that the Parties
intend that Customer’s insurance coverage will be primary over any other potentially applicable insurance. Customer shall ensure that any umbrella or excess liability coverage shall not treat the naming of Illumina as an additional insured as a
coverage change that voids or terminates such coverage. The policies may not be cancelled or amended without [...***...] prior written notice to Illumina, and the policies should so state. Customer shall maintain such insurance at all times
during the Agreement and for a period of [...***...]. 

 18. Warranty for Products. All warranties are personal to
Customer and may not be transferred or assigned to a third-party, including an Affiliate of Customer. All warranties for Products are Facility specific and do not transfer if the Product is moved to another Facility of Customer, unless Illumina
conducts such move. These warranties only apply to Products purchased under this Agreement. 
  

	 	a.	 Warranty for Consumables. Illumina warrants that TG Consumables, other than custom TG Consumables, will have no less than [...***...]
shelf-life at the time of shipment from Illumina and conform to their Specifications until the later of (i) [...***...] from the date of shipment from Illumina, and (ii) [...***...] by Illumina, but in no event later than
[...***...] from the date of shipment. Illumina warrants that Non- TG Consumables, other than custom 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 13 

	 	
Non-TG Consumables, will conform to their Specifications until the later of (i) [...***...] from Illumina, and (ii) any expiration date or the end of the shelf-life pre-printed on
such Non-TG Consumable by Illumina, but in no event later than [...***...]. With respect to custom Consumables (i.e., Consumables, whether they are TG Consumables or Non-TG Consumables) made to specifications or designs made by Customer or
provided to Illumina by, or on behalf of, Customer, Illumina only warrants that the custom Consumables will be made and tested in accordance with Illumina’s standard manufacturing and quality control processes. Illumina makes no warranty that
custom Consumables will work as intended by Customer or for Customer’s intended uses. 

  

	 	b.	Warranty for Hardware. Illumina warrants that Illumina Hardware, other than Upgraded Components, will conform to its Specifications for a period of
[...***...] from Illumina unless the Illumina Hardware includes Illumina-provided installation in which case the warranty period begins on the date of installation or [...***...], whichever occurs first (such warranty to be known as the
“Base Hardware Warranty”); provided that, the Base Hardware Warranty period for Illumina Hardware that requires Customer’s signature of document after passing certain testing criteria starts on the date that the Illumina
Hardware passed such testing criteria. “Upgraded Components” means Illumina-provided components, modifications, or enhancements to Hardware that was acquired by Customer prior to the date Illumina provides these Upgraded Components.
Illumina warrants that Upgraded Components will conform to their Specifications for a period of [...***...]. Upgraded Components do not extend the warranty for the Hardware unless the upgrade was conducted by Illumina at Illumina’s
facilities in which case the upgraded Hardware shipped to Customer comes with a Base Hardware Warranty. 

  

	 	c.	Exclusions from Warranty Coverage. The foregoing warranties in Section 18(a) and (b) shall not apply to the extent a non-conformance is due to
(i) abuse, misuse, neglect, negligence, accident, improper storage, or use contrary to the Documentation (misuse includes use of a Consumable more than one time), (ii) improper handling, installation, maintenance, or repair (other than by
Illumina personnel), (iii) unauthorized alteration, (iv) acts of God, including without limitation, fire, flood, tornado, earthquake, hurricane, lightning, threat of or actual acts of terrorism or war, or (v) use with a third
party’s good not provided by Illumina (unless its Documentation or Specifications expressly state such third party’s good is for use with it). 

  

	 	d.	Sole Remedy. In the event Product does not conform to warranty, Illumina will repair or replace the Product, the choice being in its discretion. The following
states Customer’s sole remedy and Illumina’s sole obligations under the foregoing warranties. 

  

	 	i.	Consumables. Illumina will repair or replace the Consumable in its discretion. Repaired Consumables come with a warranty that is [...***...] or the
[...***...], whichever is longer, and replaced Consumables come with the same warranty as a new Consumable. With respect to replaced TG Consumables, Illumina will use commercially reasonable efforts to provide replacement TG Consumables in
Customer’s next scheduled shipment where single lot per shipment can be maintained. 

  

	 	ii.	Hardware. Illumina will repair or replace the Hardware its discretion. Illumina Hardware may be repaired or replaced with functionally equivalent, reconditioned,
or new Illumina Hardware or components (if only a component of Illumina Hardware is non-conforming). If the Illumina Hardware is replaced in its entirety, the warranty period for the replacement is [...***...], whichever is later. If only a
component is being repaired or replaced, the warranty period for such component is [...***...], whichever is longer. 

  

	 	e.	Procedure. In order to be eligible for repair or replacement under this warranty Customer must (i) promptly contact Illumina’s customer support
department to report the non-conformance, (ii) cooperate with Illumina in the diagnosis of the non-conformance, and (iii) return the Product, transportation charges prepaid, to Illumina following Illumina’s instructions or, if agreed
by Illumina, grant Illumina’s authorized repair personnel access to this Product in order to confirm the non-conformance and make repairs. 

  

	 	f.	Third-Party Goods. Illumina has no warranty obligations with respect to any goods or software originating from a third party and supplied to Customer under this
Agreement. Third-party goods or software are those that are labeled or branded with a third-party’s name. The warranty for third-party goods or software, if any, are provided by the original manufacturer. Illumina will cooperate with Customer
in filing any warranty claims with such third-parties. 

  

	19.	Term; Cancellation; Termination. 

  

	 	a.	Term. This Agreement shall commence on the Effective Date and terminate 5 years thereafter (the “Term”) unless otherwise terminated early as
provided hereunder. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 14 

	 	b.	Cancellation of Orders. All Purchase Orders accepted by Illumina are non-cancelable by Customer and may not be modified without the prior written consent of
Illumina. 

  

	 	c.	Termination. Without limiting any other rights to terminate expressly provided in this Agreement or under law, this Agreement may be terminated early as follows:

  

	 	i.	Breach of Agreement. If either Party materially breaches this Agreement and fails to cure such breach within [...***...] after receiving written notice of
the breach, the non-breaching Party shall have the right to terminate this Agreement by providing written notice to the other Party. The Parties agree that a material breach of Section 3.a (Rights Accompanying Purchase – Consumables), 3.b
(Rights Accompanying Purchase – Illumina Hardware and Software), 3.c (Existing Instruments), 5 (Limitation on Use), 17.g (Insurance), 22.g (Assignment) or 22.h (Export) is a material breach of this Agreement. 

 

	 	ii.	Bankruptcy. Either Party may terminate this Agreement, effective immediately upon written notice, if the other Party becomes the subject of a voluntary or
involuntary petition in bankruptcy or any proceeding relating to insolvency, receivership, liquidation or composition for the benefit of creditors that is not dismissed within [...***...]. In the event of any bankruptcy or insolvency
proceeding commenced by or against Customer, Illumina shall be entitled to cancel any Purchase Order then outstanding and not accept any further Purchase Order until bankruptcy or insolvency proceeding is resolved. 

 

	 	iii.	Continuous Supply Failure. Subject to the terms and conditions of this Agreement, Customer may terminate this Agreement early by providing [...***...]
prior written notice in the event Illumina does not provide TG Consumables or Temporary Consumables for valid Purchase Orders accepted by Illumina for a period of [...***...]. 

 

	 	d.	Right to Cease Delivery. In addition to any other remedies available to Illumina under this Agreement, in equity, or at law, Illumina reserves the right to cease
shipping Product to Customer immediately if Customer (1) uses the Product outside the scope of the rights expressly conferred to Customer pursuant to Section 3 (Rights Accompanying Purchase) of this Agreement, (2) fails to pay
undisputed invoices that are [...***...] past due, (3) materially breaches any provision of Section 5, or (4) materially breaches any Customer representation or warranty made hereunder. 

20. Survival of Obligations All provisions of this Agreement that by their nature should survive termination or expiration of the Agreement shall
survive termination or expiration, including without limitation, Sections 1 (Definitions), 2.a (Applicability of Terms and Conditions – Exclusive Terms), 3.a (Rights Accompanying Purchase – Consumables), 3.b (Rights Accompanying Purchase
– Illumina Hardware and Software), 3.d (Rights Accompanying Purchase – Software), 4.a. (Additional Rights), 5 (Limitations on Use), 7.a (Pricing; Purchase Orders – Pricing), 7.c (Pricing; Purchase Orders – Payment Instead of
Taking TG Consumable), 7.e,( (Pricing; Purchase Orders – On Time Deliveries) 8 (Invoices; Payment; Taxes), 9 (Shipping Terms; Title and Risk Loss), 13.a (Regulatory; Quality Audits – Research Use), 13.b (Regulatory; Quality Audits –
Regulatory Approvals), 14 (Limitation of Liability), 15 (Limited Warranties), 16 (Confidentiality) , 17 (Indemnity; Insurance), 18 (Warranty for Products), 19 (Term; Cancellation; Termination), 20 (Survival of Obligations), 21 (Governing Law), and
22 (Miscellaneous), and all payment obligations incurred hereunder. Termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or
expiration nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with respect to any breach of this Agreement, nor prejudice either Party’s right to obtain performance of any obligation.

 21. Governing Law. This Agreement and performance by the Parties hereunder shall be construed in accordance with the laws of the State
of New York, U.S.A., without regard to provisions on the conflicts of laws. 
  

	22.	Miscellaneous. 

  

	 	a.	Representations and Warranties. 

  

	 	i.	Customer. Customer represents and warrants that (i) it owns or leases the Facilities; (ii) it has the right and authority to enter into this Agreement;
(ii) it has all rights and licenses necessary to purchase and use the Products; (iii) it does not require a license to any Illumina Application Specific IP, including without limitation, any Affiliate Application Specific IP in order to
use the Products; (iv) when performing Customer Use, it will only use the TG Consumables and Temporary Consumables; (v) it will use the Non-TG Consumables only for Research Use; and (vi) the person(s) signing this Agreement on its
behalf has the right and authority to bind Customer to the terms and conditions of this Agreement. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 15 

	 	ii.	Illumina. Illumina represents and warrants that (i) it has the right and authority to enter into this Agreement, (ii) it has all rights and licenses
necessary to sell the Products in accordance with the terms and conditions of this Agreement, and (iii) the person signing this Agreement on its behalf has the right and authority to bind Illumina to the terms and conditions of this Agreement.

  

	 	b.	Customer Inventory of Spare Parts. If Customer and Illumina agree to house spare parts for Illumina Hardware at Customer’s Facility the terms and conditions
of Appendix II shall govern such spare parts. In the event of any conflict between the terms and conditions of Appendix II and the terms and conditions of this Agreement, the terms and conditions of Appendix II shall supersede.

  

	 	c.	Illumina Affiliates. Customer agrees that Illumina may delegate its performance under this Agreement to one or more of its Affiliates. Illumina invoices and
other documentation may come from an Illumina Affiliate and Customer shall honor those just as if they came directly from Illumina. 

  

	 	d.	Legal Compliance. Nothing in this Agreement is intended, or should be interpreted, to prevent either Party from complying with all applicable laws, regulations,
or governmental orders. 

  

	 	e.	Documentation; Hierarchy of Documents. Customer agrees that it shall use the Documentation in accordance with the restrictions set forth therein (e.g.,
restrictions against altering, modifying or copying, or removing the Documentation from Customer’s facility), and further agrees that it will use Products in accordance with the Product Documentation. Notwithstanding anything to the contrary in
the Documentation, Specifications, or EULA in the event of inconsistency between the terms and conditions of this Agreement and the term of such documents, the terms and conditions of this Agreement shall supersede and control. In no event will any
such documents [...***...] when such use otherwise complies with this Agreement. Permitted copies of the Documentation shall include Illumina’s copyright and other proprietary notices. 

 

	 	f.	Severability; No Waiver. If any provision of this Agreement is held invalid or unenforceable, such provision shall be enforced to the maximum extent permissible
so as to effect the intent of the Parties, and the remainder of this Agreement will continue in full force and effect. The failure of either Party to exercise any right granted herein or to require any performance of any term of this Agreement or
the waiver by either Party of any breach of this Agreement shall not prevent a subsequent exercise or enforcement of, or be deemed a waiver of any subsequent breach of, the same or any other term of this Agreement. 

 

	 	g.	Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations under this Agreement, whether voluntary, by operation of law or
otherwise, without the prior written consent of the other Party; provided, however, that no consent shall be required for any assignment in connection with any merger, acquisition or the sale of all or substantially all of the stock or assets of a
Party to a party that agrees in writing to be bound by the terms and conditions of this Agreement, and [...***...], and (ii) Illumina may assign this Agreement to any Affiliate without Customer’s written consent. Any assignment or
transfer of this Agreement made in contravention of the terms hereof shall be null and void. Subject to the foregoing, this Agreement shall be binding on and inure to the benefit of the Parties’ respective successors and permitted assigns.

  

	 	h.	Export. Customer agrees that the Consumables, or any related technology provided under this Agreement may be subject to restrictions and controls imposed by the
United States Export Administration Act and the regulations thereunder (or the regulations and laws of another country). Customer agrees not to export or re-export the Consumables, or any related technology into any country in violation of such
controls or any other laws, rules or regulations of any country, state or jurisdiction. 

  

	 	i.	Notices. All notices required or permitted under this Agreement shall be in writing and shall be deemed received when (i) delivered personally; (ii) 5
days after having been sent by registered or certified mail, return receipt requested, postage prepaid (or 10 days for international mail); or (iii) 1 day after deposit with a commercial express courier specifying next day delivery or, for
international courier packages, 2 days after deposit with a commercial express courier specifying 2-day delivery, with written verification of receipt. All notices shall be sent to the following or any other address designated by a party using the
procedures set forth in this Sub-Section: 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 16 

			
	 If to Illumina:
  

Illumina, Inc.
 5200 Illumina Way

San Diego, CA 92122
 Attn: Sr. VP. Translational
Consumer Genomics
	  	 If to Customer
 Foundation
Medicine Inc
 One Kendall Square, B3501

Cambridge MA 02139
 Attn: Chief Business
Officer

		
	With a copy to:	  	With a copy to:
		
	 Illumina, Inc.
 5200 Illumina
Way
 San Diego, CA 92122
 Attn: General
Counsel
	  	 Foundation Medicine Inc
 One
Kendall Square, B3501
 Cambridge MA 02139
 Attn: General Counsel

  

	 	j.	Force Majeure. Neither Party shall be responsible for any failure to perform or delay in the performance of this Agreement attributable in whole or in part to
any cause beyond its reasonable control, including but not limited to acts of God, fire, flood, tornado, earthquake, hurricane, lightning, government actions, actual or threatened acts of war, terrorism, civil disturbance or insurrection, sabotage,
labor shortages or disputes [...***...], failure or delay in delivery by Illumina’s suppliers or subcontractors, transportation difficulties, shortage of energy, raw materials or equipment, or the other Party’s fault or negligence (a
“Force Majeure Event”). In the event of any delay caused by a Force Majeure Event, the delivery date for performance shall be deferred for a period equal to the time lost by reason of the delay. Notwithstanding anything in this
Agreement to the contrary, Customer’s payment obligations are not affected by this provision.  

  

	 	k.	Entire Agreement; Amendment; Waiver. This Agreement represents the entire agreement between the Parties regarding the subject matter hereof and supersedes all
prior discussions, communications, agreements, and understandings of any kind and nature between the Parties. No amendment to this Agreement will be effective unless in writing and signed by both Parties. No waiver of any right, condition, or breach
of this Agreement will be effective unless in writing and signed by the Party who has the right to waive the right, condition or breach and delivered to the other Party. Customer agrees that (i) actual knowledge by Illumina, Illumina’s
Affiliates, or their respective directors, officers, employees, or agents that Customer is using Product in any manner or for any purpose outside the scope of the rights expressly granted to Customer in Section 3 (Rights Accompanying Purchase)
does not (A) waive or otherwise limit any rights that Illumina, or Illumina’s Affiliates, may have as a result of such use of the Product, including without limitation, any rights or remedies available under the terms and conditions of
this Agreement, and any rights or remedies available at law or in equity, (B) grant Customer a license to any intellectual property owned or controlled by Customer or Customer’s Affiliates whether by implication, estoppel, or otherwise
with respect to such use of the Product, and (ii) any trade usage, and any course of performance or course of dealing between Illumina and Customer, will not be used to interpret the terms and conditions of this Agreement, including without
limitation, the scope of the rights for Product conferred under Section 3 (Rights Accompanying Purchase). 

  

	 	l.	Relationship of the Parties; No Third-Party Beneficiaries. The Parties are independent contractors under this Agreement and nothing contained in this Agreement
shall be construed as creating a partnership, joint venture or agency relationship between the Parties or, as granting either Party the authority to bind or contract any obligation in the name of the other Party, or to make any statements,
representations, warranties or commitments on behalf of the other Party. 

  

	 	m.	 Publicity; Use of Names or Trademarks; Disclosure of Agreement. Each Party shall obtain the prior written consent of the other on all press
releases or other public announcements relating to this Agreement, including its existence or its terms; provided that, Customer may issue a press release relating to the execution of this Agreement promptly following the Effective Date, the form
and substance of which shall be mutually agreed upon by the Parties. Notwithstanding any of the foregoing, if required by law, including without limitation by the U.S. Securities and Exchange Commission or any stock exchange or Nasdaq, then a Party
may issue a press release or other public statement regarding this Agreement or file a copy of this Agreement as an exhibit to a public filing; provided that, the other Party has received prior written notice of such intended press release, public
statement or disclosure and an opportunity to seek a protective order or confidentiality treatment if practicable under the circumstances and the right to propose redactions to this Agreement if it is to be filed as an exhibit to a public filing and
such proposals not to be 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 17 

	 	
unreasonably refused, and the Party subject to the requirement cooperates with the other Party to limit the disclosure and includes in such press release, public statement or disclosure only to
the minimum amount of information relating to this Agreement as is required by such law. Except as required by applicable law or regulations, neither Party shall use the name or trademarks of the other Party without the express prior written consent
of the other Party. 

  

	 	n.	 Headings; Interpretation; Miscellaneous. Sections, titles and headings in this Agreement are for convenience only and are not intended to affect
the meaning or interpretation hereof. This Agreement has been negotiated in the English language. Any translation is for convenience only. Only the English language version shall control. Whenever required by the context, the singular term shall
include the plural, the plural term shall include the singular, and the gender of any pronoun shall include all genders. As used in this Agreement except as the context may otherwise require, “include”, “includes”,
“including”, and “such as” are deemed to be followed by “without limitation”, whether or not they are in fact followed by such words or words of like import, and “will” and “shall” are used
synonymously. Except as expressly stated, any reference to “days” shall be to calendar days, and “business day” shall mean all days other than Saturdays, Sundays or a national or local holiday recognized in the United States, and
any reference to “calendar month” shall be to the month and not a 30 day period, and any reference to “calendar quarter” shall mean the first 3 calendar months of the year, the 4-6th calendar months of the year, the 7-9th calendar months of the year, and the last 3 calendar months of the
year. Whenever the last day for the exercise of any privilege or the discharge of any duty hereunder shall fall on a Saturday, Sunday, or national holiday, the Party having such privilege or duty shall have until 5:00 pm PST on the next succeeding
business day to exercise such privilege or to discharge such duty. It is further agreed that no usage of trade or other regular practice between the Parties hereto shall be used to interpret or alter the terms of this Agreement. Ambiguities, if any,
in this Agreement shall not be construed against any particular Party, irrespective of which Party may be deemed to have authored the ambiguous provision. Illumina is constantly innovating and developing new products or new versions of products. If
specific products are listed in this Agreement, Illumina is not guaranteeing that the specific products will be manufactured throughout the Term. 

  

	 	o.	Counterparts. This Agreement may be executed in one or more counterparts, and each of which shall be deemed to be an original, and all of which shall constitute
one and the same instrument. 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their
respective duly authorized representatives. 
  

									
	Customer:	 		 	Illumina:
					
	By:	 	/s/ Steven J. Kafka	 		 	By:	 	/s/ Nicholas Naclerio
	Name:	 	Steven J. Kafka, Ph.D.	 		 	Name:	 	Nicholas Naclerio
	Title:	 	Chief Operating Officer	 		 	Title:	 	SVP Corporate & Venture Development
					
	Date:	 	24 July 2013	 		 	Date:	 	7/25/2013

  
 ILLUMINA
CONFIDENTIAL 
 18 

 Exhibit A 
 Products 
 Product Prices [...***...]. 

All Product prices in the tables below are at the List Price in effect on the Effective Date. List prices [...***...]. Discounts are calculated as
set forth in Exhibit A-1. 
 Only those Products listed in this Exhibit, as may be amended from time-to-time in writing by the Parties, may
be purchased under this Agreement. 
 Consumables 
 TG Consumables Parts and Prices 
  

							
	 TG Part Number
	  	 Description        
	  	 	  	 List Price    

	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]

 Non-TG Consumables (solely for Research Uses) Parts and Prices 

[...***...] provided that, any purchases of Non-TG Consumables shall be subject to the terms and conditions of this Agreement.

 Temporary Consumables 
  

							
	 Part Number
	  	 Description    
	  	  	  	 List Price    

	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]

  

	*	Temporary Consumables [...***...] pursuant to the terms and conditions of this Agreement. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 19 

 Illumina Hardware 
  

							
	 Part Number
	  	 Description    
	  	 	  	 List Price    

	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]

 Service Contract Pricing 
  

							
	 Part Number
	  	 Description    
	  	 	  	 List Price    

	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]
	 [...***...]
	  	[...***...]	  		  	[...***...]

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 20 

 Exhibit A-1 
 Product Discounts 
 Quotes 
 First Quote. As used herein, price refers to Net Price. Illumina will provide Customer a quotation referencing this Agreement and specifying the price for each Consumable (the “First
Quote”). The First Quote and pricing found therein expires at the end of the [...***...] (e.g., [...***...]) of the Agreement and sets forth the pricing that will be used on all Purchase Orders that are provided by Customer
prior to the end of such period. The Purchase Orders placed against the First Quote must reference the First Quote and this Agreement to be valid. The pricing for the First Quote will be determined using the Consumable pricing formula set forth
below. Subject to the terms and conditions of this Agreement, if Customer desires to purchase additional Consumables that are available for purchase under this Agreement Customer may request a quote for those additional Consumables and Illumina
shall provide an updated First Quote to Customer. 
 [...***...] Quotes for Consumables. As used herein, price refers to Net Price.
No later than [...***...] prior to the start of each [...***...] (i.e., [...***...]) of this Agreement (each a “[...***...]”), Illumina will issue a quotation referencing this Agreement
and [...***...] (the “[...***...] Quote”). Each [...***...] Quote and pricing found therein expires at the end of the [...***...] that starts following the date the [...***...] Quote is due and
sets forth the pricing that will be used on all Purchase Orders that are provided by Customer prior to the end of such [...***...]. The Purchase Orders placed against each [...***...] Quote must reference the [...***...] Quote and
this Agreement to be valid. The pricing for [...***...] Quotes will be determined using the Consumable pricing formula set forth below. Subject to the terms and conditions of this Agreement, if Customer desires to purchase additional
Consumables that are available for purchase under this Agreement Customer may request a quote for those additional Consumables and Illumina shall provide an updated [...***...] Quote to Customer. 

Consumable Pricing Formula 

Customer’s purchase price for Consumables will be [...***...] the amount calculated using Discount Formula A and Discount Formula B.

  

			
	 Discount Formula

		
	A*    	  	The purchase price equals [...***...].
		
	B	  	The purchase price equals [...***...].

  

	*	This discount formula will terminate and no longer be available as of [...***...] 

 

			
	 Consumable Discount

	 Consumable Spend
	  	 Discount off of Base Price    

	[...***...]	  	[...***...]
	[...***...]	  	[...***...]
	[...***...]	  	[...***...]
	[...***...]	  	[...***...]
	[...***...]	  	[...***...]

 Illumina Hardware Discount 
 Customer’s [...***...]. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 21 

 Illumina Hardware and Service Contract Discount 

 

							
	 Tier
	  	 Hardware    
	  	 Qty.    
	  	 Discount off of Base Price    

	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]	  	[...***...]

 Illumina Qualification Services Price Table 

 

					
	 Instrument
	  	Single Certification per
Instrument (IQ, OQ or IPV)	  	Bundled Certification per
Instrument (IQ/OQ only)
	 [...***...]
	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]
	 [...***...]
	  	[...***...]	  	[...***...]

 Illumina Service Contract Discount  
 [...***...] 
  

			
	 Instrument Number
	  	 Discount off [...***...] Price

	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]
	 [...***...]
	  	[...***...]

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 22 

 Exhibit B 
 Form of Forecast 
 Example Only 

 

							
	[...***...]	  	[...***...]	  	[...***...]	  	
	[...***...]	  	[...***...]	  	[...***...]	  	
	[...***...]	  	[...***...]	  	[...***...]	  	
	[...***...]	  	[...***...]	  	[...***...]	  	
	[...***...]	  	 [...***...]

[...***...]
 [...***...]

[...***...]
	  	

  
 ***A Table
One-Page in Length is being Omitted Pursuant to the Confidential Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 23 

 Attachment 1 
 First Forecast 
 TG Consumables Only 

 

																													
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 24 

 Appendix I 
 Service Contract 
 The following section outlines the components of Gold Platinum and
Decided On-Site Service levels. Gold and Platinum Service Contracts are for a period of 12 months and must be renewed prior to their expiration by placing a Purchase Order with Illumina. The [...***...] Service level requires
[...***...], as well as the purchase of a Parts-Only contract per instrument. 
  

	1.	Gold, Platinum and Dedicated On-Site Service Levels. 

  

	 	1.1.	Technical Support Coverage 

 The
technical support hours available to the Customer are outlined in the table below. As services or times change going forward, the customer will be notified. 
  

							
	Time (EST)	 	Method of Contact	  	Contact Information	  	Location of Support Group
	8 AM – 10 AM	 	E-mail with call back	  	[...***...]	  	 East Coast

	10 AM – 8 PM	 	Direct Phone	  	[...***...]	  	 WestCoast

 Weekday holiday coverage is available via email and limited phone replies. Currently there is no
[...***...] Technical Support available over [...***...]. Additional coverage options are [...***...], and Illumina [...***...] the Customer [...***...] of any changes made in the future. 

 

	 	1.2.	Gold Level. The Gold Service level provides the Customer with full coverage on all service parts and labor as well as 5 x 24 e-mail support and 5 x 18 telephone support
(instrument, applications, and bioinformatics). This service level also includes a two business day average on-site response time from Technical Support dispatch, hardware and software critical and non-critical updates, applications support, access
to online training modules, and discounts on optional advanced training programs; provided that, Illumina’s technical support group is notified of the dispatch request prior to [...***...]. The Gold Service Level also includes
[...***...]. 

  

	 	1.3.	Platinum Level. This Platinum Service level provides the Customer with full coverage on all service parts and labor as well as 5 x 24 e-mail support and 5 x 18
telephone support (instrument, applications, and bioinformatics). This service level also includes one business day average on-site response time from Technical Support dispatch, hardware and software critical and non-critical updates, applications
support, access to online training modules, and discounts on optional advanced training programs; provided that, Illumina’s technical support group is notified of the dispatch request prior to [...***...]. This Platinum Service contract
includes [...***...]. 

  

	 	1.4	Dedicated On-Site Service Level. Customer may upgrade its desired Service Level at any time during the Term to the Dedicated On-Site Service Level as described below
upon providing written notice to Illumina, in which event Customer will be obligated to (i) pay Illumina [...***...]. At Customer’s request prior to upgrading its Service Level to the Dedicated On-Site Service Level, Illumina will
provide Customer with information regarding the quantity and cost of spare parts used by Customer historically to enable Customer to evaluate whether it desires to upgrade to the Dedicated On-Site Service Level. 

Dedicated On-Site Service Contract which supplies the Customer with a qualified dedicated Field Service Engineer that will be staffed at
the Customer Facility on a full time basis. This level of support requires a Parts-Only contract agreement for each instrument placed under this level of support and a [...***...]. After [...***...] Customer may cancel the Dedicated
On-Site Service and revert to Gold or Platinum Service with [...***...] days prior written notice to Illumina. This Service Level includes hardware and software critical and non-critical updates, applications support, access to online training
modules, and discounts on optional advanced training programs. The Dedicated On-Site Service Level also includes [...***...] preventative maintenance services a year. The standard hours of the Dedicated On-Site Field Representative will be
determined jointly by the Customer and Illumina at the start of the Dedicated On-Site Service. 
  

	 	1.5	If Customer is a Gold Service Level customer, [...***...]. Under these Service Terms Customer will receive a response from the appropriate Field Service Engineer,
Customer Solutions representative or Technical Support staff (as applicable) within 4 hours of notification by Customer, provided that Customer provides such notification within the hours specified in Section 1.1. above.

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 25 

	 	1.6.	In the event of an instrument that has seen [...***...] and continues to be [...***...] after [...***...] attempts, the decision to remedy the issue
by replacing the instrument will be at the discretion of the Director of Service Business, Director of Field Service and Regional Manager of Field Service. 

 

	 	1.7.	All service events will be logged and documented in Field Visit Reports that will be provided to the Customer by the Field Representative upon conclusion of each
service event and will also be made available to Customer in electronic format. These reports will outline (i) the diagnostic testing performed on each instrument to determine the underlying issue (ii) all repairs done on the instrument
and any parts replaced and (iii) all verification performed during the service to ensure sufficient repair and functionality of the instrument. . 

  

	 	1.8.	The Customer will be notified of any new updates or major changes to instrumentation and a basic explanation of the changes will be provided upon request. If additional
Customer on-site training is requested, the Customer is able to purchase FAS visits on an hourly basis. In addition, training services that are available to the Customer can be found at www.illumina.com under the Support > Training > Course
Catalog link. Illumina will work closely to ensure these needs are met. 

  

	 	1.9.	Site Installed Base Description 

  

									
	 Asset Name
	  	Asset Description	 	Installation Date	 	Service Level	 	Expiration Date
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]
	[...***...]	  	[...***...]	 	[...***...]	 	[...***...]	 	[...***...]

 Illumina’s Service Contracts are subject to the following terms, conditions, and limitations. 

 

	 	1.	Definitions. “Covered Hardware” means those portions of the Hardware that are covered by a Service Contract purchased by Purchaser hereunder.
“Current Specifications” means Seller’s written specifications for the Covered Hardware that apply to such Covered Hardware as provided in the Service Contract that is purchased hereunder, but only if the purchased Service
Contract provides that the Covered Hardware will conform to current specifications rather than the Original Specifications. “Purchaser” means the person or entity acquiring the Service Contract from Seller.
“Documentation” means Seller’s user manual, package insert, and similar documentation, for the Covered Hardware in effect on the date that such Covered Hardware shipped from Seller. Documentation may have contained additional
terms and conditions that are hereby incorporated herein by reference. Documentation may have been provided (including by reference to a website) with the Covered Hardware at time of shipment or provided electronically from Seller.
“EULA” means the end user license agreement for Software. “Facility” means the physical address where Covered Hardware is located. “Hardware” means Seller branded instruments, accessories, or
peripherals. “Original Specifications” means Seller’s written specifications for the Covered Hardware in effect on the date that such Covered Hardware shipped from Seller. “Original Terms” means the Seller
terms and conditions of sale in effect on the date the Covered Hardware was shipped from Seller setting forth the terms and conditions of Purchaser’s purchase and use of such Covered Hardware, components thereof, and Software.
“Quotation” means a written quotation provided by Seller to Purchaser for the Service Contract. “Seller” means Illumina. The Selling entity is identified on the quotation, order acknowledgment or similar
communication, or Seller website if the order is being placed electronically at Seller’s website. “Specifications” means the Current Specifications or the Original Specifications, as applicable; provided that, Specifications
shall in all cases refer to the Original Specifications unless otherwise set forth in the Service Contract. “Site” means the smallest definable room that contains the Covered Hardware. “Software” means Seller
branded software provided by Seller with the Covered Hardware. All Software is licensed and not sold and may be subject to additional terms found in the Software’s end user license agreement. “Term” means the length of the term
of the Service Contract. 

  

	 	2.	Term. All Service Contracts are for a period of 12 months, unless otherwise agreed to in writing by Seller or as set forth in the relevant Quotation.

  

	 	3.	 Response Time and On-site Support. Seller will use commercially reasonable efforts to respond to Purchaser’s requests for service within
the time period specified in the Service Contract. All requests for service must be made through Seller’s customer support organization (“Purchaser Solutions”). Please refer to Seller’s website for

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 26 

	 	
Purchaser Solutions contact information. Seller reserves the right to provide service and support by any method in its sole discretion, including but not limited to, remote instruction via
telephone, Internet or email, mailing to Purchaser replacement parts or test equipment, exchanging Purchaser’s component equipment with loaner equipment while repairs are being made, and deploying service or applications personnel for on-site
services. Other than installation and preventative maintenance visits, Seller shall determine in its sole discretion whether and when any personnel or replacement parts or equipment are to be sent to Purchaser’s site. Seller shall respond to
Purchaser’s request for support in accordance with the average response time specified in the Service Contract. Seller will provide a minimum number of on-site support visits as specified in the Service Contract if the Purchaser has identified
a specific need that can be fulfilled by the visit and if the Purchaser has made reasonable accommodation for scheduling the visit. If no need is identified and the timing of any visit cannot be scheduled at a mutually-agreeable date and time,
Seller may provide fewer visits than prescribed in the Service Contract. 

  

	 	4.	Software Support. During the Term, Seller shall use commercially reasonable efforts to provide all Software updates and qualified Software upgrades in accordance
with the terms of the Service Contract as such materials become commercially available for distribution. Purchaser’s use of all Software, updates, and upgrades of Software shall be subject to this Agreement, the Original Terms, and the
applicable EULA. 

  

	 	5.	Hardware Support. During the Term, Seller shall use commercially reasonable efforts to install mandatory Hardware updates in accordance with the terms of the
Service Contract as such materials become available for distribution. Whether a Hardware update is mandatory shall be determined by Seller in its sole discretion. Seller shall reschedule Hardware updates to coincide with preventive maintenance
visits. If Purchaser requests that such Hardware updates occur at a time or date other than during preventive maintenance visits, Seller may, at its sole discretion, charge Purchaser for any costs and expenses incurred in connection with such
Hardware update visit. All updated Hardware and components thereof and Purchaser’s use of the same shall be subject to this Agreement and the Original Terms.  

 

	 	6.	Hardware Repairs. Seller shall use commercially reasonable efforts to repair Covered Hardware reported by Purchaser and deemed inoperable by Seller’s
Purchaser Solutions personnel. Seller’s sole obligation hereunder is to provide parts and labor according to the terms of the Service Contract and is limited to only repair or replacement of Seller branded parts originally provided by Seller to
Purchaser. All repaired or replaced items and Purchaser’s use of the Covered Hardware including the repaired or replaced components shall be subject to this Agreement and the Original Terms. For clarity, repaired or replaced items will be
warranted to conform to the Specifications for 90 days from the date of installation or repair of such repaired or replaced item. 

  

	 	7.	Documentation Updates. Seller shall use commercially reasonable efforts to provide updates to Documentation according to the terms of the Service Contract as
they become available for distribution. Whether a Documentation update is mandatory shall be determined by Seller in its sole discretion. All updates to Documentation and Purchaser’s use of the Documentation shall be subject to this Agreement
and the Original Terms. 

  

	 	8.	Replacement Parts. All replacement parts and components provided by Seller will be new or refurbished, in Seller’s sole discretion, and shall be furnished
on an exchange basis. All Hardware or components thereof or other parts removed for replacement shall become the property of Seller. All replaced parts and components and Purchaser’s use of the Covered Hardware including the replaced parts and
components shall be subject to this Agreement and the Original Terms. For clarity, repaired or replaced items will be warranted to conform to the Specifications for [...***...] from the date of installation or repair of such repaired or
replaced item. 

  

	 	9.	Loaner Hardware. Seller may choose to provide, in its sole discretion, loaner hardware or components to Purchaser to substitute for the Covered Hardware or a
component thereof, while service is being provided. Seller will be responsible for all costs associated with the shipment of such loaner hardware or components to Purchaser’s Site, exclusive of any taxes or duties, which are the sole
responsibility of Purchaser. Loaner hardware or components shall be certified by Seller’s Purchaser Solutions using the same criteria as used for new hardware or components. Loaner hardware or components shall remain the sole property of
Seller, and must be returned within 30 days of Seller’s request. Purchaser’s use of loaner hardware or components shall be subject to Seller’s current terms and conditions of sale that apply to such loaner hardware or component.

  

	 	10.	 Preventative Maintenance Visits. Seller will provide a preventative maintenance on-site visit according to the terms of the Service Contract,
which may result in two to three days of system down time to Purchaser. Seller shall cooperate with Purchaser to schedule such preventative maintenance visits at a time that is mutually convenient for both parties. All such preventative maintenance
services will be provided by Seller designated service personnel. All travel, labor and parts/materials expenses associated with prescribed preventative maintenance visits, visits to service, repair or replace covered items, and applications support
visits as provided for in the Service Contract are included in the price set forth for such Service Contract. Preventative maintenance services include testing and adjusting the Covered Hardware to the Specifications. If any preventative maintenance
visit within the Term is precluded due to Purchaser’s inability to provide a sufficient time period for such services and down time, Seller 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 27 

	 	
shall not be obligated to provide a substitute preventative maintenance visit. Seller shall not be liable for any economic, consequential, incidental, special or other damages or losses of any
kind resulting from the down time during such preventative maintenance visits. 

  

	 	11.	Purchaser Responsibilities. 

  

	 	a.	Proper Use: The performance of Covered Hardware when operated in corrosive environments, or in conditions, or in a manner, outside of the Specifications including
Seller’s site requirements found in the Documentation or not in accordance with its Documentation may have their performance adversely affected, and are therefore not guaranteed hereunder. The Purchaser agrees to use the Covered Hardware in a
safe and reasonable manner pursuant to the Documentation and the Original Terms. 

  

	 	b.	Access: The Purchaser will provide Seller with access to the Covered Hardware along with adequate working space and facilities within a reasonable distance of the
Covered Hardware. Access will also be provided to all information and facilities that are reasonably necessary for Seller to service the Covered Hardware. 

  

	 	c.	Data Back-up and Security: The Purchaser is responsible for maintaining a procedure to reconstruct any lost or altered files, data, or programs, as well as for the
security of all confidential, proprietary, and classified information. 

  

	 	d.	Networking: The Purchaser is responsible for maintaining all computer networking as it relates to the integration of any components of the Covered Hardware outside of
such system and within the Purchaser’s network. 

  

	 	e.	Representative: A representative of Purchaser will be present on-site at all times service is being performed by Seller’s designated service personnel.

  

	 	f.	Toxic/BioHazardous Substances: The Purchaser will notify Seller in writing if any Covered Hardware is used for analysis of toxic, hazardous or dangerous substances.
Such Covered Hardware must be decontaminated by Purchaser in accordance with Seller’s decontamination procedures and Purchaser shall fax a completed and executed Decontamination Certificate to Purchaser Solutions before any service may be
performed on the Covered Hardware. 

  

	 	g.	Environment: The Purchaser agrees to provide Seller’s designated service personnel with a safe environment for their work. 

 

	 	h.	Disposal of Waste Products: The Purchaser is responsible for the proper disposal of waste products that result from maintenance and service work on the Covered
Hardware. 

  

	 	i.	Facilities: The Purchaser is responsible for ensuring that the Site will adhere to Seller’s site requirements found in the Documentation or Specifications. Any
material deviation from Seller’s site requirements affecting the proper functioning of the Covered Hardware shall relieve Seller of its obligations under this Agreement, including without limitation, under the Service Contract.

  

	 	12.	Exclusions and Restrictions. The terms of this Agreement cover maintenance and repair for conditions that result from normal use and operation as described in
the Documentation for the Covered Hardware. Seller will not be obligated to perform maintenance or repair on any Covered Hardware which, in its reasonable judgment: 

 

	 	a.	Has been subjected to abuse, misuse, neglect, negligence, accident, improper testing, improper installation other than installation performed by Seller authorized
personnel, improper storage, improper handling, or use contrary to any instructions issued by Seller or has been used in any manner inconsistent with its Documentation: 

 

	 	b.	Has been repaired, altered, disassembled, reassembled, or damaged as a result of modifications made to the Covered Hardware that were not authorized in writing by
Seller; 

  

	 	c.	Has been damaged by environmental conditions at the Site; 

  

	 	d.	Has not been installed, operated, repaired and maintained in accordance with its Documentation or has been damaged due to operators failing to perform standard
operating procedures or routine maintenance as prescribed in the applicable Documentation; 

  

	 	e.	Has been moved from the Site by persons not expressly authorized in writing by Seller; 

 

	 	f.	Has been used with any third party software, hardware, or item including, without limitation, reagent which has not been previously approved in writing by Seller;

  

	 	g.	Has been exposed to Bio-safety Level 3 or 4 agents (as defined by The Occupational Safety and Health Administration); 

 

	 	h.	Has been exposed to radioactivity, and has not been decontaminated to below exempt levels; or 

 

	 	i.	Has been damaged due to an act of Force Majeure as defined herein. 

  

	 	13.	Services by Third Parties on Seller’ Behalf. Seller reserves the right to retain or contract outside vendors of its choosing to provide service and support
hereunder. In any instance where the terms and conditions of such vendor’s service, support, and warranty agreement conflicts with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall govern; provided,
however that any exclusions on coverage contained in an OEM vendor’s terms and conditions shall remain in full force and effect. 

  
 ILLUMINA
CONFIDENTIAL 
 28 

	 	14.	Relocation of Hardware. All Service Contracts terminate automatically with immediate effect and without the need for notice to Purchaser if Covered Hardware is
moved to a different Facility. Upon such termination, Seller will credit Purchaser’s account with Seller an amount equal to the unused portion of the Service Contract; provided that, Purchaser pre-paid for the Service Contract in full. If
Seller conducts the move of the Covered Hardware on Purchaser’s behalf then Seller and Purchaser will enter into a new Service Contract for such Covered Hardware at the new Facility. 

 

	 	15.	Export of Hardware. Purchaser agrees not to move or relocate Covered Hardware outside of the country to which Seller originally shipped it without the expressly
written authorization of an officer of Seller. 

  

	 	16.	Recertification Requirement. Hardware not under an existing Service Contract is only eligible for a Service Contract if Seller has inspected the Hardware and its
ancillary equipment and provided a written notice to Purchaser that the Hardware is eligible for a Service Contract (“Recertification Requirement”). Purchaser acknowledges that Hardware may have to be repaired, at Purchaser’s
sole expense, prior to being eligible for a Service Contract. Accordingly, Seller recommends that Purchaser renew its existing Service Contracts prior to their expiration. 

 

	 	17.	Renewal of Service Contract. If Purchaser renews the Service Contract on a piece of Covered Hardware prior to the expiration of the Service Contract Seller will
waive the Recertification Requirement. 

  

	 	18.	Early Termination of Service Contract. Purchaser or Seller may, in their sole discretion, terminate the Service Contract early by providing 30 days prior written
notice to the other. Upon such termination, Seller will credit Purchaser’s account with Seller an amount equal to the unused portion of the Service Contract; provided that, Purchaser pre-paid for the Service Contract in full; and provided
further that, the amount of such credit will be reduced by the amount of any discount Seller provided Purchaser as a result of Seller purchasing a multi-year Service Contract (“Unearned Discount”). In the event Purchaser’s
Unearned Discount exceeds the amount of credit that Seller would provide under this provision, Seller will invoice Purchaser the difference and such invoice shall be paid within 30 days. 

 

	 	19.	Non-Transferable. All Service Contracts are personal to the original Purchaser of the Covered Hardware and may not be transferred or assigned to any third
party. 

  

	 	20.	Force Majeure. Seller is not responsible for any failure to perform or delay attributable in whole or in part to any cause beyond its reasonable control,
including but not limited to acts of God, fire, flood, tornado, earthquake, hurricane, lightning, government actions, actual or threatened acts of war, terrorism, civil disturbance or insurrection, sabotage, labor shortages or disputes, failure or
delay in delivery by Seller’s suppliers or subcontractors, transportation difficulties, shortage of energy, raw materials or equipment, or Purchaser’s fault or negligence. In the event of any such delay the delivery date shall be deferred
for a period equal to the time lost by reason of the delay. 

  

	 	21.	Unauthorized Activities. Purchaser agrees not to, nor authorize any third party to, engage in any of the following activities: (i) disassemble,
reverse-engineer, reverse-compile, or reverse-assemble the Covered Hardware or an items provided hereunder (collectively “Materials”), (ii) separate, extract, or isolate components of the Materials or subject the Materials or
components thereof to any analysis not expressly authorized in the Documentation, (iii) gain access to or attempt to determine the methods of operation of the Materials, or (iv) transfer to a third-party, or grant a sublicense to, any
Software or any third-party software provided hereunder. Purchaser further agrees that the contents of and methods of operation of the Materials are proprietary to Seller and the Materials contains or embodies trade secrets of Seller.

  

	 	22.	Limited Liability. TO THE EXTENT PERMITTED BY LAW, IN NO EVENT SHALL SELLER OR ITS SUPPLIERS BE LIABLE TO PURCHASER OR ANY THIRD PARTY FOR COSTS OF
PROCUREMENT OF SUBSTITUTE PRODUCTS OR SERVICES, LOST PROFITS, DATA OR BUSINESS, OR FOR ANY INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, CONSEQUENTIAL, OR PUNITIVE DAMAGES OF ANY KIND ARISING OUT OF OR IN CONNECTION WITH, WITHOUT LIMITATION, THE SALE OF
THE COVERED HARDWARE OR SERVICE CONTRACT, THE USE OF THE COVERED HARDWARE, THE ITEMS AND SERVICES PROVIDED HEREUNDER, SELLER’S PERFORMANCE HEREUNDER OR ANY OF THESE TERMS AND CONDITIONS, HOWEVER ARISING OR CAUSED AND ON ANY THEORY OF LIABILITY
(WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE). 

 TO THE EXTENT
PERMITTED BY LAW, SELLER’S TOTAL AND CUMULATIVE LIABILITY TO PURCHASER OR ANY THIRD PARTY ARISING OUT OF OR IN CONNECTION WITH THESE TERMS AND CONDITIONS, INCLUDING WITHOUT LIMITATION, THE COVERED HARDWARE OR ITEMS PROVIDED HEREUNDER (INCLUDING
USE THEREOF), THE SERVICE CONTRACT, THE 

  
 ILLUMINA
CONFIDENTIAL 
 29 

 
SERVICES PROVIDED HEREUNDER, AND SELLER’S PERFORMANCE HEREUNDER, WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY OR OTHERWISE, SHALL IN NO EVENT EXCEED
[...***...].  
  

	 	23.	Limitations on Warranties. TO THE EXTENT PERMITTED BY LAW AND SUBJECT TO THE EXPRESS WARRANTIES MADE IN THESE TERMS AND CONDITIONS SELLER MAKES NO (AND
EXPRESSLY DISCLAIMS ALL) WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE COVERED HARDWARE, THE ITEMS PROVIDED HEREUNDER, THE SERVICE CONTRACTS, AND THE SERVICES PROVIDED HEREUNDER, INCLUDING WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR ARISING FROM COURSE OF PERFORMANCE, DEALING, USAGE OR TRADE.  

  

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 30 

 Appendix II 
 Customer Inventory of Spare Parts 
  

	 	1.	Target Inventory. Illumina and Customer will mutually agree in writing upon the quantity of and type of Parts to be held by Customer at Customer’s Facility
(“Target Inventory”). Illumina will ship Customer the Target Inventory [...***...] of the Effective Date. 

  

	 	2.	Shipping; Title and Risk of Loss. Customer is responsible for all costs associated with the shipping and transportation of Parts to the Facility. Title to the
Parts remains with Illumina until the Parts are used in Equipment. Risk of loss for the Parts transfers to Customer upon delivery of the Parts to the Facility. 

 

	 	3.	Incoming Inspection; Inventory. Customer will inspect the Parts for damage upon receipt and record the amount and type of Parts received, the date and time of
receipt, and serial numbers (if applicable). Customer will provide Illumina with written notice of any damaged Parts within 5 business days of their receipt. All Parts not identified as damaged within such 5 business day time period shall be
considered the consigned inventory (“Inventory”). Customer shall, unless otherwise specified by Illumina, send any damaged Parts back to Illumina at Illumina’s expense [...***...] of receipt by Customer.

  

	 	4.	Consignment Fee. Customer will pay Illumina an amount equal to [...***...] for the Target Inventory once per calendar year as a consignment fee
(“Consignment Fee”). The Consignment fee is non-refundable. Illumina will invoice Customer the Consignment Fee promptly after the Effective Date. 

 

	 	5.	Authorized Personnel Only. Only Illumina authorized personnel (“Service Personnel”) may withdraw Parts from the Inventory and/or install such Parts on
the Equipment. 

  

	 	6.	Storage and Possession. Customer will use reasonable care and best industry practices to maintain and store the Parts at the Facility. Customer will store the
Parts separate from other parts at the Facility so that Parts are only accessible to Service Personnel (preferably in a locker with a key). Illumina may take possession of any Parts at any time up to the point of installation of the Parts by
providing reasonable notice to Customer. Customer will cooperate and provide reasonable assistance to Illumina to regain possession of the Parts. Customer will not cause or permit any liens or encumbrances to attach to the Parts or any other
property of Illumina at the Facility. 

  

	 	7.	[...***...] Usage and Count. Customer will perform a count of all Parts in Inventory [...***...] and provide Illumina a written reporting containing
the Part numbers, quantities of Parts in Inventory, Part description, and Part serial number (if applicable) (“[...***...] Count”). If the [...***...] Count is below the Target Inventory, Illumina will replenish the Inventory
and Illumina will issue an invoice to Customer for such usage unless such Part(s) is covered under a then-current and valid Illumina service contract that covers the full cost of such Part. In the event of discrepancies, Customer will be invoiced
for Parts that are missing from Inventory and have not already been paid for by Customer already. 

  

	 	8.	Final Inventory Reconciliation; Disposition. Illumina will conduct a final count of Inventory during the last [...***...] of this Agreement (“Final
Inventory Count”) Customer will either purchase from Illumina all Parts remaining in Inventory (or otherwise received by Customer and not yet paid for) as of the Inventory count date, return the unused Parts to Illumina, or renew this Agreement
for a mutually agreed upon subsequent term. Illumina shall be responsible for packaging and shipping such Parts back to Illumina if the Parts are returned to Illumina pursuant to this Section. If any Parts returned to Illumina are used or damaged
(not due to shipment back to Illumina) at the time of Illumina’s receipt, Illumina will invoice the Customer for such Parts. 

  

	 	9.	Payment. Customer will make full payment of all invoices within [...***...] of the date of invoice. Any amounts not paid when due will accrue interest at
the rate of [...***...], or the maximum amount allowed by law, if lower. Customer shall pay for all costs (including reasonable attorneys’ fees) incurred by Illumina in connection with the collection of payments. All prices for Parts are
the price in effect on the date of Illumina’s invoice. 

  

	 	10.	Audits. Customer will keep accurate books and records related to the Parts. Illumina has the right to audit, at Illumina’s expense, such Customer books and
records in connection with this Agreement and the Parts supplied hereunder. 

  

	 	11.	Compliance with Laws. Each Party agrees to comply with all applicable laws, regulations, and guidelines in connection with the management of Inventory under this
Agreement. Customer will provide Illumina reasonable access to the Facility to inspect the Parts upon prior written notice. 

  

	 	12.	Representations and Warranties. Customer represents and warrants that (i) the Facility will be maintained in good condition, (ii) the Parts will only
be used with Illumina Equipment and for no other purposes, and (iii) it will not install and will not allow a third party to install the Parts (other than Service Personnel) on Equipment, unless otherwise authorized in writing by Illumina, and
(iv) it will not sell, lease, or otherwise transfer the Parts to a third party without Illumina’s prior written consent. 

  
 ***Confidential
Treatment Requested*** 

  
 ILLUMINA
CONFIDENTIAL 
 31 

	 	13.	No Reverse Engineering. Customer agrees that Customer shall not, nor will Customer use or permit any third party to, engage in any of the following activities
without the express prior written permission of an officer of Illumina: (i) disassemble, reverse-engineer, reverse-compile, or reverse-assemble the Parts or the Equipment, (ii) separate, extract, or isolate components of the Parts or the
Equipment or subject the Parts and/or Equipment or components thereof to any analysis not expressly authorized in writing by Illumina, or (iii) otherwise gain access to or determine the methods of operation of the Parts or the Equipment.

  

	 	14.	Proprietary Information. Customer agrees that the contents, design, materials, properties, formulation, methods and techniques of operation and manufacture of
the Parts and Equipment are the proprietary and trade secret information of Illumina and may not be disclosed to any third party and may not be used in any manner except as expressly authorized in writing by an officer of Illumina.

  
 ILLUMINA
CONFIDENTIAL 
 32EX-10.15

 EXHIBIT 10.15 
  

 
 August 1, 2011 
 Vincent Miller, MD 
  

	Re:	Offer of Employment with Foundation Medicine, Inc. 

 Dear Vince: 
 It is with great pleasure that I offer you employment with Foundation Medicine, Inc.
(“Foundation Medicine” or “the Company”). Your initial position will be Senior Vice President, Clinical Development, reporting to Michael Pellini, MD, President and Chief Executive Officer. You will be a member of the
Company’s Executive Management Team. In addition to performing duties and responsibilities associated with the position above, from time-to-time the Company may assign you other duties and responsibilities consistent with such position. Your
effective date of hire as a regular, full-time employee is preferred to be October 15, 2011. 
 Salary and Expense Reimbursement.
You will be paid on a salary basis at an annual rate of $335,000.00, payable twice per month in accordance with Foundation Medicine’s standard payroll practices and subject to customary deductions and withholdings as required by law. You will
be eligible for annual merit salary reviews in accordance with the Company’s compensation practices. Also, the Company will reimburse your reasonable out-of-pocket travel expenses and other expenses related to your work based on the
Company’s expense reimbursement policy. 
 Sign-on Bonus. You will be paid a sign-on bonus in the amount of $100,000. This sign-on
bonus will be paid in two installments. The first installment of $50,000 will be paid to you on the Company’s first regular pay date following your actual start date, provided such date is not less than 5 days after your actual start date, and
will be subject to customary deductions and withholdings as required by law. The second payment of $50,000 will be paid to you on March 31, 2012 (or if such date is not one of the Company’s regular pay dates, then on the Company’s
first regular pay date thereafter) if you remain employed by the Company at such time, or promptly following your termination of employment for Good Reason (as defined below) within three (3) months of the initial existence of the condition or
event that constitutes Good Reason, and will be subject to customary deductions and withholdings as required by law. Should you voluntarily leave the Company, other than for Good Reason within three (3) months of the initial existence of the
condition or event that constitutes Good Reason, within one year of receiving payment of either installment (or both installments) of the sign-on bonus, you will be obligated to return the gross amount of such installment(s) to the Company within 30
days of your departure date. 

			
	

	  	
		  	 V. Miller Offer Letter
 August 1, 2011
  Page
 2

  

 Living Assistance. Foundation Medicine acknowledges that you live in New Jersey and as a
condition of your employment you will be commuting to the Company’s offices in Massachusetts. In the absence of relocation, the Company will provide you with annual Living Expense Assistance of up to $35,000 annually. This allowance will be
paid to you directly in the form of expense reimbursements in accordance with the Company’s expense reimbursement plan, and may be subject to customary deductions and withholdings as required by law. 

Possible Annual Bonus Opportunity. At the time of this offer, the Company has not established an annual bonus program, and the
establishment of an annual bonus program (and terms and conditions of an annual bonus program) would be subject to the discretion of the Board (or its Compensation Committee). However, if and when the Company adopts an annual bonus program generally
covering senior management of the Company (which would start applying no earlier than January 1, 2012), during your employment with the Company during each period when an annual bonus program is applicable, you shall be eligible to receive an
annual incentive bonus as part of such annual bonus program with a target of up to thirty five percent (35%) of your annual base salary paid for such year, as determined by the Board (or its Compensation Committee) based on the terms and
conditions of such annual bonus program. 
 Restricted Stock Grant; Options to Purchase Stock. As an incentive for you to share in
the long-term growth of Foundation Medicine, it is our intention to recommend to the Board of Directors that you be issued 550,000 shares of Foundation Medicine’s common stock (the “Restricted Stock”) upon your payment of a purchase
price of $0.02 per share. The Restricted Stock will be governed by a stock restriction agreement (in the standard form approved by Foundation Medicine’s Board of Directors), and will be subject to the provisions of Foundation Medicine’s
then-current stock incentive plan. The stock restriction agreement will also describe the vesting of the Restricted Stock (through the mechanism of a lapsing repurchase right in favor of the Company), which will be as follows: the Restricted Stock
will vest over a four-year period, with 25% vesting on the first anniversary of the actual start date, and an additional 6.25% vesting on the last business day of each calendar quarter for the next twelve successive quarters of employment, until
100% of the shares of Restricted Stock have become vested, provided that you are still employed by Foundation Medicine on each such vesting date. 
 Further, it is our intention also to recommend to the Board of Directors that you be granted two additional stock options (collectively, the “Subsequent Options”) promptly after your actual
start date as follows: 
  

	 	•	 	 an option to purchase 100,000 shares of Foundation Medicine’s common stock, with an exercise price per share equal to the fair market value per
share of such common stock on the date of grant, and with vesting over a four-year period, with 6.25% vesting on [December 31, 2012], and an additional 6.25% vesting on 

  

www.foundationmedicine.com 

			
	

	  	  
 V. Miller Offer Letter

August 1, 2011
  Page

 3

  

	 	 
the last business day of each calendar quarter for the next fifteen successive quarters of employment, until 100% of the shares underlying such option have become vested, provided that you are
still employed by Foundation Medicine on each such vesting date; and 

  

	 	•	 	 an option to purchase 100,000 shares of Foundation Medicine’s common stock, with an exercise price per share equal to the fair market value per
share of such common stock on the date of grant, and with vesting over a four-year period, with 6.25% vesting on [December 31, 2013], and an additional 6.25% vesting on the last business day of each calendar quarter for the next fifteen successive
quarters of employment, until 100% of the shares underlying such option have become vested, provided that you are still employed by Foundation Medicine on each such vesting date. 

Each of the Subsequent Options will be governed by a stock option agreement (in the standard form approved by Foundation Medicine’s Board of
Directors), and will be subject to the provisions of Foundation Medicine’s then-current stock incentive plan. 
 Subject to the further
provisions of this letter, vesting of the Restricted Stock and the Subsequent Options (if any) will accelerate with regard to the entire remaining unvested portion of the Restricted Stock and the Subsequent Options (if any) after (a) a
“Deemed Liquidation Event” (as defined in the Company’s Amended and Restated Certificate of Incorporation, as amended) and (b) any one of the following events: (i) the Company subsequently electing to terminate your
employment with the Company without “Cause” (as defined below), (ii) you subsequently terminating your employment with the Company for “Good Reason” within three (3) months of the initial existence of the condition or
event that constitutes Good Reason, or (iii) you continuing employment with the Company (or its successor) for twelve (12) months following such Deemed Liquidation Event. 
 Severance. Without otherwise limiting the “at will” nature of your employment, in the event that the Company elects to terminate your employment without Cause (as defined below), or if
you terminate your employment for Good Reason within three (3) months of the initial existence of the condition or event that constitutes Good Reason, for a period of 12 months following termination, the Company will continue to pay you your
base salary rate in effect on the date of termination, and pay Company-paid COBRA continuation medical and dental benefits for you (and your eligible dependents). These severance benefits shall commence within 60 days after the date your employment
terminates, provided that if such 60 day period begins in one calendar year and ends in a second calendar year, such severance benefits shall commence in the second calendar year and, provided, further that if such severance benefits do not begin
immediately on the date your employment terminates, the first payment thereof shall contain a “catch up” payment including all amounts that would have been paid had such severance benefits commenced on the date your employment terminated.
In order to receive these severance benefits and/or the acceleration of vesting contemplated in the preceding paragraph (under “Restricted Stock Grant; Options to Purchase Stock”) if such acceleration occurs as a result of a termination of
your employment with the Company, you will be required 

  

www.foundationmedicine.com 

			
	

	  	  
 V. Miller Offer Letter

August 1, 2011
  Page

 4

  

 
to execute and not revoke a separation agreement with the Company that includes a general release of all known and unknown claims that you may then have against the Company or persons affiliated
with the Company in a form provided by the Company. Such separation agreement shall also provide that for three (3) years following your termination of employment that: (i) you covenant and agree that you will not make any disparaging
comments, statements or communications about the Company, its affiliates, stockholders, directors, officers, employees or agents, or its management or business practices, and (ii) the Company will not (and the Company will instruct the Board of
Directors and the senior executive officers of the Company to not) make any disparaging comments, statements or communications about you, provided, that these provisions shall not prohibit any party (A) from disclosing that you are no
longer employed by the Company; (B) from responding truthfully to any governmental investigation, legal process or related inquiry; (C) from making reasonable competitive statements in the course of promoting a competing business, so long
as any statements described in this clause (C) do not violate the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement described below; or (D) making a good faith rebuttal of the other party’s
untrue or misleading statement. As used in this paragraph, the term “disparage” means any statements, whether orally, in writing or through any medium (including, but not limited to, the press or other media, computer networks or bulletin
boards, or any other form of communication), that intentionally disparage, defame, or otherwise damage or assail the reputation, integrity or professionalism of the other party. 
 For the purposes of this Agreement, “Cause” means that one or more of the following events has occurred: 
  

	 	(i)	conviction of a felony; 

  

	 	(ii)	willful failure to substantially perform (other than by reason of disability) your duties and responsibilities as set forth in, or determined in accordance with, this
letter that results in material harm to the Company, which failure continues, or which harm remains unremedied, after ten (10) days’ notice setting forth in reasonable detail the nature of such failure; 

 

	 	(iii)	material breach by you of any provision of this letter that results in material harm to the Company, which breach continues or remains uncured after ten (1 0)
days’ notice setting forth in reasonable detail the nature of such breach; or 

  

	 	(iv)	material fraudulent conduct by you with respect to the Company. 

 For purposes of this letter, “Good Reason” means the occurrence of one or more of the following without your written consent, provided that you have complied with the Good Reason Process (as
defined below): 
  

	 	(i)	a material diminution in your responsibilities, authority or duties as Senior Vice President, Clinical Development; 

 

	 	(ii)	a material diminution in your base salary, except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or
substantially all senior management employees of the Company; or 

  

	 	(iii)	a material breach by the Company of this letter or any of the agreements you have with the Company relating to the Restricted Stock, the Subsequent Options, or other
equity of Foundation Medicine. 

  

www.foundationmedicine.com 

			
	

	  	  
 V. Miller Offer Letter

August 1, 2011
  Page

 5

  

 For purposes of this letter, the “Good Reason Process” means that (a) you reasonably
determine that a Good Reason condition has occurred, (b) you notify the Company in writing of the first occurrence of the Good Reason condition within sixty (60) days of the first occurrence of such condition, (c) you cooperate in
good faith with the Company’s efforts, for a period of not less than thirty (30) days following such notice (the “Cure Period”), to remedy the Good Reason condition, (d) notwithstanding such efforts the Good Reason condition
continues to exist, and (e) you terminate your employment within sixty (60) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

 In the event that your employment is terminated by the Company for Cause, or by you without Good Reason (or with Good Reason but not within
three (3) months of the initial existence of the condition or event that constitutes Good Reason), you shall be entitled to receive only any base pay earned through the date of termination. 

Section 409A Compliance. Any severance payments to you pursuant to the Severance section above, for clarity including the acceleration
of vesting contemplated in the Restricted Stock Grant; Options to Purchase Stock section above (and the corresponding provisions in any stock restriction agreement and/or stock option agreement between the Company and you, if applicable) if such
acceleration occurs as a result of a termination of your employment with the Company shall begin only after the date of your “separation from service” (within the meaning of Section 409A of the Internal Revenue Code of 1986 (as
amended or replaced) (the “Code”),which may occur on or after the date of the termination of your employment, and shall be subject to the following provisions: 

 

	 	(i)	It is intended that each installment of the severance payments (and the corresponding provisions in any stock restriction agreement and/or stock option agreement
between the Company and you, if applicable) shall be treated as a separate “payment” for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments
except to the extent specifically permitted or required by Section 409A. 

  

	 	(ii)	If, as of the date of your “separation from service” from the Company, you are not a “specified employee” (within the meaning of Section 409A),
then each installment of the severance payments shall be made on the dates and terms set forth in this letter (and the corresponding provisions in any stock restriction agreement and/or stock option agreement between the Company and you, if
applicable). 

  

www.foundationmedicine.com 

			
	

	  	  
 V. Miller Offer Letter

August 1, 2011
  Page

 6

  

	 	(iii)	If, as of the date of your “separation from service” from the Company, you are a “specified employee” (within the meaning of Section 409A),
then: 

  

	 	A.	Each installment of the severance payments that, in accordance with the dates and terms set forth in this letter, will in all circumstances, regardless of when the
“separation from service” occurs, be paid within the Short-Term Deferral Period (as defined below) shall be treated as a “short-term deferral” within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum
extent permissible under Section 409A. “Short-Term Deferral Period” means the period ending on the later of the 15th day of the third month following the end of your tax year in which the “separation from service” occurs and
the 15th day of the third month following the end of the Company’s tax year in which the “separation from service” occurs; and 

  

	 	B.	Each installment of the severance payments that is not described in clause (iii)(A) above and that would, absent this clause (B), be paid within the six-month period
following your “separation from service” from the Company shall not be paid until the date that is six months and one day after such “separation from service” (or, if earlier, your death), with any such installments that are
required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your “separation from service” and any subsequent installments, if any, being paid in
accordance with the dates and terms set forth in this letter; provided, however, that the preceding provisions of this clause (B) shall not apply to any installment of severance payments and benefits if and to the maximum extent that that such
installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from
service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-l(b)(9)(iii) must be paid no later than the last day of your second taxable year following the taxable year in which the “separation from
service” occurs. 

  

	 	(iv)	The determination of whether and when your “separation from service” from the Company has occurred shall be made in a manner consistent with, and based on the
presumptions set forth in, Treasury Regulation Section 1.409A-l(h). Solely for purposes of this paragraph (iv), “Company” shall include all persons with whom the Company would be considered a single employer under Sections 414(b) and
414(c) of the Code. 

  

	 	(v)	All reimbursements and in-kind benefits provided under this letter shall be made or provided in accordance with the requirements of Section 409A to the extent that
such reimbursements or in-kind benefits are subject to Section 409A. 

  

www.foundationmedicine.com 

			
	

	  	  
 V. Miller Offer Letter

August 1, 2011
  Page

 7

  

	 	(vi)	Notwithstanding any other provision of this letter (or in any stock restriction agreement and/or stock option agreement between the Company and you, if applicable), the
Company shall have no liability to you or to any other person if any provisions of this letter that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant. 

Benefits. As a regular, full-time employee, you will be eligible to participate in the employee benefit plans that Foundation Medicine
offers to its employees in comparable positions. Descriptions of the Company’s benefit plans will be available upon request. These plans may be amended or terminated from time-to-time with or without prior notice. In addition, you will be
entitled to up to fifteen (15) days of vacation each calendar year and to such other holidays as Foundation Medicine recognizes for employees having comparable responsibilities and duties. For any calendar year in which you are employed with
the Company for only a portion of such year, your vacation allowance will be pro-rated. 
 Terms of Employment. Your employment at all
times will be “at will,” meaning that you are not being offered employment for a definite period and that either you or Foundation Medicine may terminate the employment relationship at any time, for any lawful reason, with or without
cause. However, you agree to give us fourteen (14) days’ written notice if you decide to terminate the employment relationship, and we agree to give you fourteen (14) days’ written notice if we decide to terminate the employment
relationship (except in situations where we reasonably believe our business will be harmed by our continued employment of you for such period, in which case we may terminate you immediately). The substantive law of the Commonwealth of Massachusetts
will govern your employment with Foundation Medicine. 
 Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement. As
part of your employment with Foundation Medicine, you will be exposed to, and provided with, valuable confidential and/or trade secret information concerning Foundation Medicine and its present and future business plans and operations. As a result,
in order to protect Foundation Medicine’s legitimate business interests, you agree, as a condition of your employment, to sign the Company’s Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement, a
copy of which is attached to this letter as Exhibit A. 
 No Conflicting Agreements. We understand that you currently are not
subject to any agreements that restrict your activities for Foundation Medicine. By accepting this offer, you represent that you are not subject to any agreements which might restrict your conduct at Foundation Medicine; and that you understand that
if you become aware at any time during your employment with Foundation Medicine that you are subject to any agreements which might restrict your conduct at Foundation Medicine, you are required to immediately inform Foundation Medicine of the
existence of such agreements or your employment by Foundation Medicine could be subject to termination. 

  

www.foundationmedicine.com 

			
	

	  	  
 V. Miller Offer Letter

August 1, 2011
  Page

 8

  

 I-9 Employment Verification Form. In addition, the Immigration Reform and Control Act requires
employers to verify employment eligibility and identity of new employees. This offer of employment is contingent on your signing an I-9 Employment Verification Form no later than your first day of employment, and you must provide us with appropriate
documents to establish your eligibility to work in the United States (for example, Social Security Card, Drivers’ License, U.S. Passport). We will not be able to employ you if you fail to comply with this requirement. 

Entire Agreement. This letter, together with Exhibit A (which is incorporated into this letter by reference), will constitute the entire
agreement as to your employment relationship with Foundation Medicine and will supersede any prior agreements or understandings, whether in writing or oral. 
 Offer Expiration. This offer will expire at 5:00PM, Eastern Time, on Friday, August 5, 2011. Please indicate your acceptance of this offer and the terms and conditions thereof by signing both
this letter and Exhibit A, and returning fully signed copies to me at Foundation Medicine. 
 We are looking forward to your joining the
Foundation Medicine team! We are confident that you will find a great deal of challenge, satisfaction, and opportunity for personal and professional growth at Foundation Medicine. 

 

			
	Sincerely,
	
	FOUNDATION MEDICINE, INC.
		
	By:	 	 /s/ Michael J. Pellini

		 	Michael J. Pellini, MD
		 	President and Chief Executive Officer

 YOU ACKNOWLEDGE THAT YOU HAVE CAREFULLY READ THIS LETTER, INCLUDING EXHIBIT A, AND UNDERSTAND AND AGREE TO ALL OF THE
PROVISIONS IN THIS LETTER AND ITS EXHIBITS. 
  

			
	Accepted and agreed by:
	
	 /s/ Vincent A. Miller

	Employee Signature
	
	 Vincent A. Miller

	Print Employee’s Name
		
	Date:	 	 3 August 2011

  

www.foundationmedicine.com 

 EXHIBIT A 
 Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement 

  

www.foundationmedicine.com 

 Standard Foundation Medicine Form 
 New Employee Agreement 
 Revisions Approved November 29, 2010 

MODIFIED FOR VINCENT MILLER, MD 
  

 
 Non-Competition, Non-Solicitation, 

Confidentiality and Assignment Agreement 
 In consideration and as a condition of my employment or continued employment by Foundation Medicine, Inc. (the “Company”), I hereby agree as follows: 

 

 1. Proprietary Information. I agree that all information, whether or not in writing, whether or not
disclosed before or after I was first employed by the Company, concerning the Company’s business, technology, business relationships or financial affairs that the Company has not released to the general public (collectively, “Proprietary
Information”), and all tangible embodiments thereof, are and will be the exclusive property of the Company. By way of illustration, Proprietary Information may include information or material that has not been made generally available to the
public, such as: (a) corporate information, including plans, strategies, methods, policies, resolutions, notes, email correspondence, negotiations or litigation; (b) marketing information, including strategies, methods,
customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements,
equity structure, investors and holdings, purchasing and sales data and price lists; and (d) operational and technological information, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures,
formulas, discoveries, inventions, improvements, biological or chemical materials, concepts and ideas; and (e) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation
structure, performance evaluations and termination arrangements or documents. Proprietary Information includes, without limitation, (1) information received in confidence by the Company from its customers or suppliers or other third parties,
and (2) all biological or chemical materials and other tangible embodiments of the Proprietary Information. 
 2. Recognition of
Company’s Rights. I will not, at any time, without the Company’s prior written permission, either during or after my employment,

 
disclose or transfer any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of my duties
as an employee of the Company. I will cooperate with the Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all copies and other tangible embodiments of Proprietary
Information in my possession or control upon the earlier of a request by the Company or termination of my employment. 
 3. Rights of
Others. I understand that the Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons that require the Company to protect or refrain from use of proprietary information. I agree to be bound
by the terms of such agreements in the event I have access to such proprietary information. 
 4. Commitment to Company; Avoidance of
Conflict of Interest. While an employee of the Company, I will devote my full-time efforts to the Company’s business and I will not engage in any other business activity that conflicts with my duties to the Company. I will advise the
President of the Company or his or her nominee at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee of the Company. I will take
whatever action is requested of me by the Company to resolve any conflict or appearance of conflict that it finds to exist. 
 5.
Developments. I hereby assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns, all my right, title and interest in and to all Developments (as
defined below) that: (a) are created, developed, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction

 

			
	

	  	Page 2 of 5

  

 
(collectively, “conceived”) during the period of my employment and six (6) months thereafter and that relate to the business of the Company or to products, methods or services
being researched, developed, manufactured or sold by the Company; or (b) result from tasks assigned to me by the Company; or (c) result from the use of premises, Proprietary Information or personal property (whether tangible or intangible)
owned, licensed or leased by the Company (collectively, “Company-Related Developments”), and all patent rights, trademarks, copyrights and other intellectual property rights in all countries and territories worldwide claiming, covering or
otherwise arising from or pertaining to Company-Related Developments (collectively, “Intellectual Property Rights”). I further agree that “Company-Related Developments” include, without limitation, all Developments that
(i) were conceived by me before my employment, (ii) relate to the business of the Company or to products, methods or services being researched, developed, manufactured or sold by the Company, and (iii) were not subject to an
obligation to assign to another entity when conceived. I will make full and prompt disclosure to the Company of all Company-Related Developments, as well as all other Developments conceived by me during the period of my employment and six
(6) months thereafter. I acknowledge that all work performed by me as an employee of the Company is on a “work for hire” basis. I hereby waive all claims to any moral rights or other special rights that I may have or accrue in any
Company-Related Developments. 
 “Developments” mean inventions, discoveries, designs, developments, methods, modifications,
improvements, processes, biological or chemical materials, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship. 

If, in the course of my employment with the Company, I incorporate a Development conceived by me before my employment that are not Company-Related
Developments (“Prior Inventions”) into a Company product, process or research or development program or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual,
worldwide license (with the full right to sublicense through multiple tiers) to make, have made, modify, use, offer for sale, import and sell such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated,
Prior Inventions in any Company-Related

 
Development without the Company’s prior written consent. 
 I understand that to the
extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section will be interpreted not to
apply to any invention which a court rules and/or the Company agrees falls within such classes. 
 6. Documents and Other Materials. I
will keep and maintain adequate and current records of all Proprietary Information and Company-Related Developments conceived by me, which records will be available to and remain the sole property of the Company at all times. All files, letters,
notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, materials or other written, photographic or other tangible
material containing or embodying Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company to be used by me only in the performance of my duties for the Company. In
the event of the termination of my employment for any reason, I will deliver to the Company all of the foregoing, and all other materials of any nature pertaining to the Proprietary Information of the Company and to my work, and will not take or
keep in my possession any of the foregoing or any copies. Any property situated on the Company’s premises and owned by the Company, including laboratory space, computers, disks and other storage media, filing cabinets or other work areas, is
subject to inspection by the Company at any time with or without notice. 
 7. Enforcement of Intellectual Property Rights. I will
cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights, as well as all other patent rights, trademarks, copyrights and
other intellectual property rights in all countries and territories worldwide owned by or licensed to the Company. I will sign, both during and after the term of this Agreement, all papers, including copyright applications, patent applications,
declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development or Intellectual Property Rights. If the

 

			
	

	  	Page 3 of 5

  

 
Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and appoint each officer of the Company as my agent and attorney-in-fact to
execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in the same. 
 8. Non-Competition and Non-Solicitation. In order to protect the Company’s Proprietary Information and good will, during my employment and for a period of one (1) year following the
termination of my employment for any reason (the “Restricted Period”), I will not directly or indirectly, whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise, engage, participate or
invest in any business activity anywhere in the world that develops, manufactures or markets any products, or performs any services, that are otherwise competitive with the products or services of the Company, or products or services that the
Company has under development or that are the subject of active planning at any time during my employment; provided that this will not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the
stock of such company. In addition, during the Restricted Period, I will not, directly or indirectly, in any manner, other than for the benefit of the Company, (a) call upon, solicit, divert or take away any of the customers, business or
prospective customers of the Company or any of its suppliers, and/or (b) solicit, entice or attempt to persuade any other employee or consultant of the Company to leave the services of the Company for any reason. I acknowledge and agree that if
I violate any of the provisions of this Section, the running of the Restricted Period will be extended by the time during which I engage in such violation(s). 
 9. Government Contracts. I acknowledge that the Company may have from time to time agreements with other persons or with the United States Government or its agencies that impose obligations or
restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to comply with any such obligations or restrictions upon the direction of the Company.
In addition to the rights assigned under Section 5, I also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be in the United States under any contract
between the

 
Company and the United States or any of its agencies. 
 10. Prior Agreements. I
hereby represent that, except as I have fully disclosed previously in writing to the Company, I am not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential
or proprietary information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party. I further represent that my performance of all the terms
of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not
disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others. 
 11. Remedies Upon Breach. I understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and I consider them to be
reasonable for such purpose. Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies that may be available, will be
entitled to specific performance and other injunctive relief. 
 12. Publications and Public Statements. I will obtain the Company’s
written approval before publishing or submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. To ensure that the Company delivers a consistent message about its products,
services and operations to the public, and further in recognition that even positive statements may have a detrimental effect on the Company in certain securities transactions and other contexts, any statement about the Company which I create,
publish or post during my period of employment and for six (6) months thereafter, on any media accessible by the public, including but not limited to electronic bulletin boards and Internet- based chat rooms, must first be reviewed and approved
by an officer of the Company before it is released in the public domain. 
 13. No Employment Obligation. I understand that this
Agreement does not create an obligation on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment agreement

 

			
	

	  	Page 4 of 5

  

 
signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated by the Company or me at any time and for any reason.

 14. Survival and Assignment by the Company. I understand that my obligations under this Agreement will continue in accordance with its
express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following the
termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the right to assign this Agreement to its affiliates, successors and assigns. I
expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time of such
transfer. 
 15. Disclosure to Future Employers. I will provide a copy of this Agreement to any prospective employer, partner or
co-venturer prior to entering into an employment, partnership or other business relationship with such person or entity. 
 16. Exit
Interview. If and when I depart from the Company, I may be required to attend an exit interview and sign an “Employee Exit Acknowledgement” to reaffirm my acceptance and acknowledgement of the obligations set forth in this Agreement.
During the Restricted Period following termination of my employment, I will notify the Company of any change in my address and of each subsequent employment or business activity, including the name and address of my employer or other post-Company
employment plans and the nature of my activities. 
 17. Severability. In case any provisions (or portions thereof) contained in this
Agreement will, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such
invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity
or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.

 18. Entire Agreement. This Agreement constitutes the entire and only agreement between the Company
and me respecting the subject matter hereof, and supersedes all prior agreements and understandings, oral or written, between us concerning such subject matter. No modification, amendment, waiver or termination of this Agreement or of any provision
hereof will be binding unless made in writing and signed by an authorized officer of the Company. Failure of the Company to insist upon strict compliance with any of the terms, covenants or conditions hereof will not be deemed a waiver of such
terms, covenants or conditions. In the event of any inconsistency between this Agreement and any other contract between the Company and me, the provisions of this Agreement will prevail. 
 19. Interpretation. This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted, enforced and governed under the laws of
the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Suffolk County, Massachusetts for purposes of enforcing this Agreement, and waive any objection that I might have
to personal jurisdiction or venue in those courts. As used in this Agreement, “including” means “including but not limited to.” 
 BY SIGNING BELOW, I CERTIFY THAT I HAVE READ THIS AGREEMENT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY. 
 IN WITNESS WHEREOF, the undersigned has executed this agreement as a sealed instrument as of the date set forth below. 

 

			
	Signed:	 	 /s/ Vincent A. Miller

		 	(Employee’s full name)

  

			
	Type or print name:	 	 Vincent A. Miller

 

			
	Date:	 	 3 August 2011

 
 

			
	

	  	Page 1 of 5

  

 EXHIBIT A 

 

			
	TO:	  	Foundation Medicine, Inc.
		
	FROM:	  	
		
	DATE:	  	
		
	SUBJECT:	  	Prior Inventions

  

					
		  		  	The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company that have been made or conceived or first reduced
to practice by me alone or jointly with others prior to my engagement by the Company:
			
		  	 ̈	  	No inventions or improvements
			
		  	 ̈	  	See below:
		  		  	  

		  		  	  

		  		  	  

		  		  	  

			
		  	 ̈	  	Additional sheets attached
			
		  		  	The following is a list of all patents, patent applications and other patent rights that I have invented:
			
		  	 ̈	  	None
			
		  	 ̈	  	See below:
		  		  	  

		  		  	  

		  		  	  

		  		  	  

 

 
 March 7, 2013 
 Vincent Miller, M.D. 
 Re: Amendment to Offer of Employment with Foundation Medicine, Inc. dated
August 1, 2011 
 Dear Vince: 

Reference is made to the letter, dated August 1, 2011 (the “Agreement”), between you and Foundation Medicine, Inc.
(“Foundation”). This letter constitutes an amendment to the Agreement (this “Amendment”). Capitalized terms used herein and not otherwise defined shall have the meaning set forth in the Agreement. 

 

	1.	The last paragraph in the “Restricted Stock Grant; Options to Purchase Stock” section is hereby deleted in its entirety and replaced with the
following: 

 “In addition to the Restricted Stock and Subsequent Options, from time to time, you have
received, and you may receive, other incentive stock options, non-statutory stock options, shares of restricted stock, restricted stock units or other incentive equity awards in respect of shares of the Company’s equity securities (each an
“Equity Award” and collectively, the “Equity Awards”). 
 A list of all Equity Awards granted to you by the
Company as of the date of this Agreement is attached as Exhibit B (the “Equity Schedule”). The Equity Awards are subject to the terms and conditions of the Company’s incentive equity plan(s), as may be amended from time to time, and
associated award agreements (collectively, and together with the Equity Schedule, the “Equity Documents”). 
 Certain
Equity Awards have been granted acceleration rights described below and are designated as Acceleration Equity Awards on the Equity Schedule (the “Acceleration Equity Awards”). Equity Awards not granted Acceleration Rights by the Company
are designated as Non-Acceleration Equity Awards on the Equity Schedule (the “Non-Acceleration Equity Awards”). Any Equity Awards granted to you by the Company that are not listed on the Equity Schedule shall be considered Non-Acceleration
Equity Awards, unless and until they are granted Acceleration Equity Award status by the Board. Consistent with the Equity Documents, the Equity Schedule may be amended from time to time by the Company to add Acceleration Equity Awards or to add
Non-Acceleration Equity Awards, and to convert Non-Acceleration Equity Awards to Acceleration Equity Awards. Each amendment to the Equity Schedule shall be consecutively numbered and dated, shall make express reference to this Agreement, shall
supersede the immediately preceding Equity Schedule, and following issuance shall be incorporated into this Agreement and shall constitute one of the Equity Documents. 

 Subject to the further provisions of this letter, the Restricted Stock and the Subsequent
Options (if any) shall be designated as Acceleration Equity Awards on the Equity Schedule. Vesting of the Restricted Stock and the Subsequent Options (if any) shall accelerate with regard to the entire remaining unvested portion of the Restricted
Stock or the Subsequent Options (if any), as the case may be, after (a) a “Change in Control” (as defined below) and (b) any one of the following events: (i) the Company subsequently electing to terminate your employment
with the Company without “Cause” (as defined below), (ii) you subsequently terminating your employment with the Company for “Good Reason” within three (3) months of the initial existence of the condition or event that
constitutes Good Reason, or (iii) your continued employment with the Company (or its successor) for twelve (12) months following such Change in Control. 
 Subject to the further provisions of this Agreement and the Equity Documents, vesting of any Acceleration Equity Awards (other than the Restricted Stock and the Subsequent Options (if any), which shall be
governed by the preceding paragraph) shall accelerate with regard to the entire remaining unvested portion of such Acceleration Equity Awards in the event that within eighteen (18) months following a Change in Control (i) your employment
is terminated by the Company without Cause, or (ii) you terminate your employment with the Company for Good Reason in accordance with the Good Reason Process.” 

 

	2.	The definition of “Cause” in the “Severance” section is hereby deleted in its entirety and replaced with the following:

 “For the purposes of this Agreement “Cause” means one or more of the following events has
occurred: 
  

	 	(i)	your conviction of, or the entry of a pleading of guilty or nolo contendere to, any crime involving (a) fraud or embezzlement, or (b) any felony;

  

	 	(ii)	your willful failure to perform (other than by reason of disability), or gross negligence in the performance of, your duties and responsibilities as set forth in your
job description; 

  

	 	(iii)	a material breach by you of any provision of this Agreement, the Employee Agreement, or any of the other agreements you have with the Company, which breach continues or
remains uncured after thirty (30) days’ notice setting forth in reasonable detail the nature of such breach; or 

  

	 	(iv)	material fraudulent conduct by you with respect to the Company.” 

  

	3.	The definition of “Good Reason” in the “Severance” section is hereby deleted in its entirety and replaced with the following:

 “For the purposes of this Agreement “Good Reason” means the occurrence of one or more of the
following without your written consent, provided that you have complied with the Good Reason Process (as defined below): 
  

	 	(i)	a material diminution in your responsibilities, authority or duties as Senior Vice President, Clinical Development; 

 

	 	(ii)	a material diminution in your base salary, except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or
substantially all senior management employees of the Company; 

	 	(iii)	a material breach by the Company of this letter or any of the agreements you have with the Company relating to the Restricted Stock, the Subsequent Options, or other
equity of Foundation Medicine; or 

  

	 	(iv)	your work location is located more than fifty (50) miles from the Company’s office location at which you were principally working as of the effective date of
the Change in Control. 

 For the purposes of this Agreement, the “Good Reason Process” means that
(a) you reasonably determine that Good Reason condition has occurred, (b) you notify the Company in writing of the first occurrence of the Good Reason Condition within sixty (60) day of the first occurrence of such condition,
(c) you cooperate in good faith with the Company’s efforts, for a period of not less than thirty (30) days following such notice (the “Cure Period”), to remedy the Good Reason condition, (d) notwithstanding such efforts
the Good Reason condition continues to exist, and (e) you terminate your employment within sixty ( 60) days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not
to have occurred. 
  

	4.	The following definition is inserted as a new paragraph immediately before the last paragraph in the “Severance” section: 

“For the purposes of this Agreement “Change in Control” means the following: 

(a) prior to the completion of an initial public offering by the Company, an event that (i) is a Deemed Liquidation Event within the
meaning of such term as set forth in the Company’s Amended and Restated Certificate of Incorporation, as amended, as amended and/or restated from time to time and (ii) results in the payment of proceeds to the stockholders of the Company
and 
 (b) following the completion of an initial public offering by the Company, any of the following: 

(i) any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as
amended (the “Act”) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with
all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or
indirectly, of securities of the Company representing 50 percent or more of the combined voting power of the Company’s then outstanding securities having the right to vote in an election of the Board (“Voting Securities”) (in such
case other than as a result of an acquisition of securities directly from the Company); or 
 (ii) the date when
a majority of the members of the Board of Directors of the Company is replaced during any consecutive twenty-four month period by individuals who, prior to their election, or nomination for election by the Company’s shareholders, were not
approved by a majority of the members of the Board of Directors in existence on the date immediately prior to such election, appointment or nomination; or 
 (iii) the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the
consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the
consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of
the assets of the Company. 

 Notwithstanding the foregoing, a “Change in Control” shall not include (x) an
initial public offering and (y) shall not be deemed to have occurred for purposes of the foregoing clause (b)(i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities
outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred
to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from
the Company) and immediately thereafter beneficially owns 50 percent or more of the combined voting power of all of the then outstanding Voting Securities, then a “Change in Control” shall be deemed to have occurred for purposes of the
foregoing clause (b)(i).” 
  

	5.	The last paragraph in the “Severance” section is hereby deleted in its entirety and replaced with the following: 

“For the avoidance of doubt, you and the Company acknowledge that if your employment is terminated: (i) by the Company for
Cause, (ii) by you without Good Reason, (iii) by you with Good Reason but not within three (3) months of the initial existence of the condition or event that constitutes Good Reason), or (iv) as a result of your death or
disability, then, as a result of such termination, (w) you shall be entitled to receive only any base pay earned through the date of termination plus accrued but unused vacation pay through the date of termination, (y) the unvested portion
of your Equity Awards will not accelerate and (z) your Equity Awards shall expire or be forfeited in accordance with the terms of the Equity Documents.” 
  

	6.	This Agreement shall remain in effect if you are transferred, promoted, or reassigned to work in functions other than your current functions at Foundation. Your
obligations under this Agreement shall survive the termination of your employment with Foundation regardless of the manner or the reasons for such termination. This Amendment and the Agreement shall inure to the benefit of, and be binding upon,
Foundation and you, and our respective heirs, legal representatives, successors and assigns. This Amendment and the Agreement may be assigned by Foundation without your consent to any successor entity in the event of a merger, acquisition, change of
control, or sale of all or substantially all of the business or assets of the Company. “Foundation Medicine”, “Foundation” and “Company” shall also mean any such successor entity as the context requires.

  

	7.	Upon execution, this Amendment and the Agreement, together with Exhibits A and B, and the Equity Documents, each as amended from time to time, will constitute the
entire agreement as to your employment relationship with Foundation and will supersede any prior agreements or understandings, whether in writing or oral. 

 We are looking forward to your continued contributions as a member of the Foundation Medicine team.

  

			
	Sincerely,
	
	FOUNDATION MEDICINE, INC.
	
	 /s/ Sarah Larson

	By:	 	Sarah Larson
	Title:	 	Vice President, Human Resources

 YOU ACKNOWLEDGE THAT YOU HAVE CAREFULLY READ THIS LETTER DATED AUGUST 1, 2011, THE AMENDMENT DATED MARCH 7, 2013,
AND EXHIBIT A AND EXHIBIT B TO THIS LETTER, AND UNDERSTAND AND AGREE TO ALL OF THE PROVISIONS IN THIS LETTER AND ITS EXHIBITS. FACSIMILE AND PDF SIGNATURES SHALL HAVE THE SAME LEGAL EFFECT AS ORIGINALS. 

 

			
	Accepted and agreed by:
	
	 /s/ Vincent Miller

	Employee Signature
	
	 Vincent A. Miller

	Print Employee’s Name
		
	Date:	 	 20 Jun 2013

 EXHIBIT B 
 Equity Schedule 
 The table below contains information regarding stock option awards.
Except for information regarding the designation of a stock option award as an Acceleration Equity Award or Non-Acceleration Equity Award, the information furnished is for reference purposes only. In the event of a conflict between the information
furnished in this table and the Stock Option Agreement for such stock option award, the terms and conditions of the Stock Option Agreement shall govern. You should refer to each Stock Option Agreement for the individual terms and conditions of such
stock option award. 
  

							
	 Grant
	 	  	 Grant Date
	  	 Acceleration
Rights

	 	550,000	  	  	August 3, 2011	  	Yes
	 	100,000	  	  	January 11, 2012	  	Yes
	 	100,000	  	  	January 11, 2012	  	Yes
	 	50,000	  	  	March 7, 2013	  	Yes
	 	*50,000	  	  	May 21, 2013	  	Yes

  

	*	Grant is subject to condition vesting terms which are defined m the option agreement 

 September 10, 2013 
 Vincent Miller, M.D. 
  

	Re:	Second Amendment to Offer of Employment with Foundation Medicine, Inc. 

 Dear Vince: 
 Reference is made to the employment offer letter, dated
August 1, 2011 (the “Agreement”), between you and Foundation Medicine, Inc. (“Foundation”) and the First Amendment to the Agreement, dated March 7, 2013 (the “First Amendment”), between
you and Foundation. This letter constitutes a second amendment to the Agreement and First Amendment (the “Second Amendment”). All capitalized terms used, but not defined, herein shall have the meanings ascribed to them in the
Agreement. 
  

	 	(1)	The first paragraph of the Agreement is hereby deleted in its entirety and replaced with the following: 

“Your current position with Foundation Medicine, Inc. (“Foundation Medicine” or the “Company”) is Chief Medical
Officer, effective July 31, 2013, reporting to Michael Pellini, M.D., President and Chief Executive Officer. You are also a member of the Company’s Executive Management Team. In addition to performing duties and responsibilities associated
with the positive described above, from time to time, the Company may assign you other duties and responsibilities consistent with such position.” 
  

	 	(2)	The paragraph of the section of the Agreement entitled “Living Assistance”, shall be amended and restated in its entirety to read as follows:

 “The Company acknowledges that you live in New Jersey and as a condition of your employment you will be
commuting to the Company’s offices in Massachusetts. In the absence of relocation, the Company will reimburse or directly pay you for living expenses in Boston, Massachusetts, including executive apartment rental, utilities, internet,
telephone, television, cleaning and other customary costs associated with the executive apartment rental, and food expenses (to the extent such food expenses are not otherwise reimbursable as a business expense under the Company’s business
expense policy), in each instance as incurred in the metropolitan Boston, Massachusetts area (“Living Expenses”) up to $35,000 annually (the “Living Expenses Cap”). Any unused portion of the Living Expenses Cap, or any Living
Expenses in excess of the Living Expenses Cap shall not affect the amount of Living Expenses eligible for reimbursement in any subsequent calendar year. The Company will also reimburse or directly pay for your reasonable travel expenses incurred
annually commuting between New Jersey and Cambridge, Massachusetts (“Commuting Expenses”). 

 The Company will determine in its reasonable judgment what, if any, of your Commuting
Expenses and Living Expenses paid for or reimbursed by the Company are taxable to you in accordance with applicable law and will comply with associated withholding and tax reporting obligations. To the extent certain of these Commuting Expenses
and Living Expenses are deemed taxable by the IRS in a given year, the Company will provide you with a tax gross-up payment such that after payment of taxes (federal, state and employment) on such amount, there remains a balance sufficient to pay
the taxes (federal, state and employment) on the amount of your taxable reimbursable Commuting Expenses and Living Expenses. The Company will make such tax gross-up payment promptly but in no event later than the end of the calendar year in which
you remit the related taxes.” 
 This Second Amendment shall be treated as amending the Agreement and First Amendment.
Except as set forth herein, the Agreement and First Amendment shall otherwise remain in full force and effect in accordance with their terms. You reaffirm the effectiveness of your existing Employee Non-Competition, Non-Solicitation, Confidentiality
and Assignment Agreement, a copy of which is attached to this Second Amendment as Exhibit A. The interpretation of this Second Amendment will be governed by the laws of the Commonwealth of Massachusetts, without regard to the conflicts of
laws principles thereof. 

 Please indicate your agreement to the terms herein by countersigning in the place indicated
below. 
  

			
	FOUNDATION MEDICINE, INC.
		
	Name	 	 /s/ Sarah Larson

		
	Title	 	 Vice President, Human Resources

		
	Date	 	 September 10, 2013

  

	
	Accepted and agreed by:
	
	 /s/ Vincent Miller

	Vincent Miller, M.D.

 EXHIBIT A 
 Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment Agreement 

 Standard Foundation Medicine Form 
 New Employee Agreement 
 Revisions Approved November 29, 2010 

MODIFIED FOR VINCENT MILLER, MD 
  

 
 Non-Competition, Non-Solicitation, 

Confidentiality and Assignment Agreement 
 In consideration and as a condition of my employment or continued employment by Foundation Medicine, Inc. (the “Company”), I hereby agree as follows: 

 

 1. Proprietary Information. I agree that all information, whether or not in writing, whether or not
disclosed before or after I was first employed by the Company, concerning the Company’s business, technology, business relationships or financial affairs that the Company has not released to the general public (collectively, “Proprietary
Information”), and all tangible embodiments thereof, are and will be the exclusive property of the Company. By way of illustration, Proprietary Information may include information or material that has not been made generally available to the
public, such as: (a) corporate information, including plans, strategies, methods, policies, resolutions, notes, email correspondence, negotiations or litigation; (b) marketing information, including strategies, methods,
customer identities or other information about customers, prospect identities or other information about prospects, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements,
equity structure, investors and holdings, purchasing and sales data and price lists; and (d) operational and technological information, including plans, specifications, manuals, forms, templates, software, designs, methods, procedures,
formulas, discoveries, inventions, improvements, biological or chemical materials, concepts and ideas; and (e) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation
structure, performance evaluations and termination arrangements or documents. Proprietary Information includes, without limitation, (1) information received in confidence by the Company from its customers or suppliers or other third parties,
and (2) all biological or chemical materials and other tangible embodiments of the Proprietary Information. 
 2. Recognition of
Company’s Rights. I will not, at any time, without the Company’s prior written permission, either during or after my employment,

 
disclose or transfer any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of my duties
as an employee of the Company. I will cooperate with the Company and use my best efforts to prevent the unauthorized disclosure of all Proprietary Information. I will deliver to the Company all copies and other tangible embodiments of Proprietary
Information in my possession or control upon the earlier of a request by the Company or termination of my employment. 
 3. Rights of
Others. I understand that the Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons that require the Company to protect or refrain from use of proprietary information. I agree to be bound
by the terms of such agreements in the event I have access to such proprietary information. 
 4. Commitment to Company; Avoidance of
Conflict of Interest. While an employee of the Company, I will devote my full-time efforts to the Company’s business and I will not engage in any other business activity that conflicts with my duties to the Company. I will advise the
President of the Company or his or her nominee at such time as any activity of either the Company or another business presents me with a conflict of interest or the appearance of a conflict of interest as an employee of the Company. I will take
whatever action is requested of me by the Company to resolve any conflict or appearance of conflict that it finds to exist. 
 5.
Developments. I hereby assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns, all my right, title and interest in and to all Developments (as
defined below) that: (a) are created, developed, made, conceived or reduced to practice by me (alone or jointly with others) or under my direction

 

			
	

	  	Page 2 of 5

  

 
(collectively, “conceived”) during the period of my employment and six (6) months thereafter and that relate to the business of the Company or to products, methods or services
being researched, developed, manufactured or sold by the Company; or (b) result from tasks assigned to me by the Company; or (c) result from the use of premises, Proprietary Information or personal property (whether tangible or intangible)
owned, licensed or leased by the Company (collectively, “Company-Related Developments”), and all patent rights, trademarks, copyrights and other intellectual property rights in all countries and territories worldwide claiming, covering or
otherwise arising from or pertaining to Company-Related Developments (collectively, “Intellectual Property Rights”). I further agree that “Company-Related Developments” include, without limitation, all Developments that
(i) were conceived by me before my employment, (ii) relate to the business of the Company or to products, methods or services being researched, developed, manufactured or sold by the Company, and (iii) were not subject to an
obligation to assign to another entity when conceived. I will make full and prompt disclosure to the Company of all Company-Related Developments, as well as all other Developments conceived by me during the period of my employment and six
(6) months thereafter. I acknowledge that all work performed by me as an employee of the Company is on a “work for hire” basis. I hereby waive all claims to any moral rights or other special rights that I may have or accrue in any
Company-Related Developments. 
 “Developments” mean inventions, discoveries, designs, developments, methods, modifications,
improvements, processes, biological or chemical materials, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, audio or visual works, and other works of authorship. 

If, in the course of my employment with the Company, I incorporate a Development conceived by me before my employment that are not Company-Related
Developments (“Prior Inventions”) into a Company product, process or research or development program or other work done for the Company, I hereby grant to the Company a nonexclusive, royalty-free, fully paid-up, irrevocable, perpetual,
worldwide license (with the full right to sublicense through multiple tiers) to make, have made, modify, use, offer for sale, import and sell such Prior Invention. Notwithstanding the foregoing, I will not incorporate, or permit to be incorporated,
Prior Inventions in any Company-Related

 
Development without the Company’s prior written consent. 
 I understand that to the
extent this Agreement is required to be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes of inventions made by an employee, this Section will be interpreted not to
apply to any invention which a court rules and/or the Company agrees falls within such classes. 
 6. Documents and Other Materials. I
will keep and maintain adequate and current records of all Proprietary Information and Company-Related Developments conceived by me, which records will be available to and remain the sole property of the Company at all times. All files, letters,
notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, materials or other written, photographic or other tangible
material containing or embodying Proprietary Information, whether created by me or others, which come into my custody or possession, are the exclusive property of the Company to be used by me only in the performance of my duties for the Company. In
the event of the termination of my employment for any reason, I will deliver to the Company all of the foregoing, and all other materials of any nature pertaining to the Proprietary Information of the Company and to my work, and will not take or
keep in my possession any of the foregoing or any copies. Any property situated on the Company’s premises and owned by the Company, including laboratory space, computers, disks and other storage media, filing cabinets or other work areas, is
subject to inspection by the Company at any time with or without notice. 
 7. Enforcement of Intellectual Property Rights. I will
cooperate fully with the Company, both during and after my employment with the Company, with respect to the procurement, maintenance and enforcement of Intellectual Property Rights, as well as all other patent rights, trademarks, copyrights and
other intellectual property rights in all countries and territories worldwide owned by or licensed to the Company. I will sign, both during and after the term of this Agreement, all papers, including copyright applications, patent applications,
declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Development or Intellectual Property Rights. If the

 

			
	

	  	Page 3 of 5

  

 
Company is unable, after reasonable effort, to secure my signature on any such papers, I hereby irrevocably designate and appoint each officer of the Company as my agent and attorney-in-fact to
execute any such papers on my behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in the same. 
 8. Non-Competition and Non-Solicitation. In order to protect the Company’s Proprietary Information and good will, during my employment and for a period of one (1) year following the
termination of my employment for any reason (the “Restricted Period”), I will not directly or indirectly, whether as owner, partner, shareholder, director, consultant, agent, employee, co-venturer or otherwise, engage, participate or
invest in any business activity anywhere in the world that develops, manufactures or markets any products, or performs any services, that are otherwise competitive with the products or services of the Company, or products or services that the
Company has under development or that are the subject of active planning at any time during my employment; provided that this will not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the
stock of such company. In addition, during the Restricted Period, I will not, directly or indirectly, in any manner, other than for the benefit of the Company, (a) call upon, solicit, divert or take away any of the customers, business or
prospective customers of the Company or any of its suppliers, and/or (b) solicit, entice or attempt to persuade any other employee or consultant of the Company to leave the services of the Company for any reason. I acknowledge and agree that if
I violate any of the provisions of this Section, the running of the Restricted Period will be extended by the time during which I engage in such violation(s). 
 9. Government Contracts. I acknowledge that the Company may have from time to time agreements with other persons or with the United States Government or its agencies that impose obligations or
restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. I agree to comply with any such obligations or restrictions upon the direction of the Company.
In addition to the rights assigned under Section 5, I also assign to the Company (or any of its nominees) all rights which I have or acquired in any Developments, full title to which is required to be in the United States under any contract
between the

 
Company and the United States or any of its agencies. 
 10. Prior Agreements. I
hereby represent that, except as I have fully disclosed previously in writing to the Company, I am not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential
or proprietary information in the course of my employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party. I further represent that my performance of all the terms
of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by me in confidence or in trust prior to my employment with the Company. I will not
disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others. 
 11. Remedies Upon Breach. I understand that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and I consider them to be
reasonable for such purpose. Any breach of this Agreement is likely to cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies that may be available, will be
entitled to specific performance and other injunctive relief. 
 12. Publications and Public Statements. I will obtain the Company’s
written approval before publishing or submitting for publication any material that relates to my work at the Company and/or incorporates any Proprietary Information. To ensure that the Company delivers a consistent message about its products,
services and operations to the public, and further in recognition that even positive statements may have a detrimental effect on the Company in certain securities transactions and other contexts, any statement about the Company which I create,
publish or post during my period of employment and for six (6) months thereafter, on any media accessible by the public, including but not limited to electronic bulletin boards and Internet- based chat rooms, must first be reviewed and approved
by an officer of the Company before it is released in the public domain. 
 13. No Employment Obligation. I understand that this
Agreement does not create an obligation on the Company or any other person to continue my employment. I acknowledge that, unless otherwise agreed in a formal written employment agreement

 

			
	

	  	Page 4 of 5

  

 
signed on behalf of the Company by an authorized officer, my employment with the Company is at will and therefore may be terminated by the Company or me at any time and for any reason.

 14. Survival and Assignment by the Company. I understand that my obligations under this Agreement will continue in accordance with its
express terms regardless of any changes in my title, position, duties, salary, compensation or benefits or other terms and conditions of employment. I further understand that my obligations under this Agreement will continue following the
termination of my employment regardless of the manner of such termination and will be binding upon my heirs, executors and administrators. The Company will have the right to assign this Agreement to its affiliates, successors and assigns. I
expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary or affiliate to whose employ I may be transferred without the necessity that this Agreement be resigned at the time of such
transfer. 
 15. Disclosure to Future Employers. I will provide a copy of this Agreement to any prospective employer, partner or
co-venturer prior to entering into an employment, partnership or other business relationship with such person or entity. 
 16. Exit
Interview. If and when I depart from the Company, I may be required to attend an exit interview and sign an “Employee Exit Acknowledgement” to reaffirm my acceptance and acknowledgement of the obligations set forth in this Agreement.
During the Restricted Period following termination of my employment, I will notify the Company of any change in my address and of each subsequent employment or business activity, including the name and address of my employer or other post-Company
employment plans and the nature of my activities. 
 17. Severability. In case any provisions (or portions thereof) contained in this
Agreement will, for any reason, be held invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability will not affect the other provisions of this Agreement, and this Agreement will be construed as if such
invalid, illegal or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement will for any reason be held to be excessively broad as to duration, geographical scope, activity
or subject, it will be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it will then appear.

 18. Entire Agreement. This Agreement constitutes the entire and only agreement between the Company
and me respecting the subject matter hereof, and supersedes all prior agreements and understandings, oral or written, between us concerning such subject matter. No modification, amendment, waiver or termination of this Agreement or of any provision
hereof will be binding unless made in writing and signed by an authorized officer of the Company. Failure of the Company to insist upon strict compliance with any of the terms, covenants or conditions hereof will not be deemed a waiver of such
terms, covenants or conditions. In the event of any inconsistency between this Agreement and any other contract between the Company and me, the provisions of this Agreement will prevail. 
 19. Interpretation. This Agreement will be deemed to be made and entered into in the Commonwealth of Massachusetts, and will in all respects be interpreted, enforced and governed under the laws of
the Commonwealth of Massachusetts. I hereby agree to consent to personal jurisdiction of the state and federal courts situated within Suffolk County, Massachusetts for purposes of enforcing this Agreement, and waive any objection that I might have
to personal jurisdiction or venue in those courts. As used in this Agreement, “including” means “including but not limited to.” 
 BY SIGNING BELOW, I CERTIFY THAT I HAVE READ THIS AGREEMENT CAREFULLY AND AM SATISFIED THAT I UNDERSTAND IT COMPLETELY. 
 IN WITNESS WHEREOF, the undersigned has executed this agreement as a sealed instrument as of the date set forth below. 

 

			
	Signed:	 	 /s/ Vincent A. Miller

		 	(Employee’s full name)

  

			
	Type or print name:	 	 Vincent A. Miller

 

			
	Date:	 	 3 August 2011

 
 

			
	

	  	Page 1 of 5

  

 EXHIBIT A 

 

			
	TO:	  	Foundation Medicine, Inc.
		
	FROM:	  	
		
	DATE:	  	
		
	SUBJECT:	  	Prior Inventions

  

					
		  		  	The following is a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company that have been made or conceived or first reduced
to practice by me alone or jointly with others prior to my engagement by the Company:
			
		  	 ̈	  	No inventions or improvements
			
		  	 ̈	  	See below:
		  		  	  

		  		  	  

		  		  	  

		  		  	  

			
		  	 ̈	  	Additional sheets attached
			
		  		  	The following is a list of all patents, patent applications and other patent rights that I have invented:
			
		  	 ̈	  	None
			
		  	 ̈	  	See below:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]